PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
17992517-4	2007	The bretylium-resistant component was potentiated by the acetylcholinesterase (AChE) inhibitor neostigmine (10 microM) and inhibited by the muscarinic-receptor (mAChR) antagonist cyclopentolate (1 microM).	Neostigmine	95-106	acetylcholinesterase	Cavia porcellus	57-77
18242923-5	2008	This report discusses the utilization of neostigmine, an acetylcholinesterase inhibitor, for patients with colonic pseudo-obstruction.	Neostigmine	41-52	acetylcholinesterase (Cartwright blood group)	Homo sapiens	57-77
17950687-1	2008	The inhibition of horse serum butyrylcholinesterase (EC 3.1.1.8) by three carbamates (eserine, neostigmine, and rivastigmine) was studied by flow microcalorimetry at 37 degrees C in Tris buffer (pH 7.5).	Neostigmine	95-106	butyrylcholinesterase	Homo sapiens	30-51
19011777-2	2008	An increase in acetylcholine concentration caused by neostigmine and calcium may enhance the use-dependent ion channel block of the nicotinic acetylcholine receptor caused by clindamycin.	Neostigmine	53-64	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	132-164
17888667-6	2007	AChE inhibitory activity study was carried out by using Ellman colorimetric assay with neostigmine as a reference standard against targets from different species, such as pure electric eel AChE, human serum AChE, and rat brain AChE.	Neostigmine	87-98	acetylcholinesterase	Rattus norvegicus	0-4
18996666-1	2008	In this work, the interaction of a series of acetylcholinesterase inhibitors (AChEIs; donepezil, galanthamine, huperzine and neostigmine) with human serum albumin (HSA) immobilized on porous silica particles was studied using a biochromatographic approach.	Neostigmine	125-136	albumin	Homo sapiens	149-162
19138245-1	2008	BACKGROUND: As spinal cholinergic receptors participate in the control of somatic pain, this effect could be potentiated by intrathecal injection of a cholinesterase inhibitor, neostigmine.	Neostigmine	177-188	butyrylcholinesterase	Homo sapiens	151-165
18091537-10	2008	Animals treated with the peripheral cholinesterase inhibitor neostigmine showed no difference compared with physostigmine-treated animals.	Neostigmine	61-72	butyrylcholinesterase	Mus musculus	36-50
17872965-5	2008	Two weeks of infusion with neostigmine (6 microg kg(-1) day(-1)) or pilocarpine (0.3 mg kg(-1) day(-1)) significantly reduced cardiac hypertrophy, reduced TNF alpha levels and elevated interleukin-10 levels in heart tissues, and improved ventricular function in rats with transverse aortic constriction.	Neostigmine	27-38	tumor necrosis factor	Rattus norvegicus	155-164
17872965-5	2008	Two weeks of infusion with neostigmine (6 microg kg(-1) day(-1)) or pilocarpine (0.3 mg kg(-1) day(-1)) significantly reduced cardiac hypertrophy, reduced TNF alpha levels and elevated interleukin-10 levels in heart tissues, and improved ventricular function in rats with transverse aortic constriction.	Neostigmine	27-38	interleukin 10	Rattus norvegicus	185-199
17992517-4	2007	The bretylium-resistant component was potentiated by the acetylcholinesterase (AChE) inhibitor neostigmine (10 microM) and inhibited by the muscarinic-receptor (mAChR) antagonist cyclopentolate (1 microM).	Neostigmine	95-106	acetylcholinesterase	Cavia porcellus	79-83
17208293-5	2007	Therefore, FSM-16-TIPB was the best material, considering also that when neostigmine was applied to AChE immobilized on FSM-16-TIPB, the activity of AChE decreased as occurs in its free from.	Neostigmine	73-84	acetylcholinesterase (Cartwright blood group)	Homo sapiens	100-104
17893459-1	2007	BACKGROUND: It is standard practice to administer a cholinesterase inhibitor (e.g., neostigmine) at the end of a surgical case to reverse suspected effects of neuromuscular blocking agents regardless of whether such residual effects are present.	Neostigmine	84-95	butyrylcholinesterase	Rattus norvegicus	52-66
17893459-9	2007	CONCLUSIONS: The cholinesterase inhibitor neostigmine markedly impairs upper airway dilator volume, genioglossus muscle function, diaphragmatic function, and breathing when given after recovery from vecuronium-induced neuromuscular block.	Neostigmine	42-53	butyrylcholinesterase	Rattus norvegicus	17-31
17208293-5	2007	Therefore, FSM-16-TIPB was the best material, considering also that when neostigmine was applied to AChE immobilized on FSM-16-TIPB, the activity of AChE decreased as occurs in its free from.	Neostigmine	73-84	acetylcholinesterase (Cartwright blood group)	Homo sapiens	149-153
16627857-4	2007	Neostigmine, an acetylcholinesterase inhibitor, mimicked the actions of nicotine.	Neostigmine	0-11	acetylcholinesterase	Rattus norvegicus	16-36
17113068-0	2007	Correlations between acetylcholinesterase inhibition, acetylcholine levels and EEG changes during perfusion with neostigmine and N6-cyclopentyladenosine in rat brain.	Neostigmine	113-124	acetylcholinesterase	Rattus norvegicus	21-41
17113068-4	2007	A non-linear relationship between the acetylcholinesterase activity and the extracellular amount of acetylcholine was found, the latter being approximately three times higher in the striatum than in the hippocampus upon infusion with 10(-4) M neostigmine.	Neostigmine	243-254	acetylcholinesterase	Rattus norvegicus	38-58
16582934-13	2006	The cholinesterase inhibitor neostigmine (0.3 ng, i.t.)	Neostigmine	29-40	butyrylcholinesterase	Mus musculus	4-18
17156201-10	2006	Nicotine-induced signals reflected the hydrolysis of ACh by endogenous acetylcholinesterase (AChE) as inhibition of the enzyme following perfusion with neostigmine (10 microm) attenuated the signal (40-94%).	Neostigmine	152-163	acetylcholinesterase	Rattus norvegicus	71-91
17156201-10	2006	Nicotine-induced signals reflected the hydrolysis of ACh by endogenous acetylcholinesterase (AChE) as inhibition of the enzyme following perfusion with neostigmine (10 microm) attenuated the signal (40-94%).	Neostigmine	152-163	acetylcholinesterase	Rattus norvegicus	93-97
17122235-1	2006	We previously demonstrated the effectiveness of epidural sufentanil and the cholinesterase inhibitor, neostigmine, to initiate selective labor analgesia.	Neostigmine	102-113	butyrylcholinesterase	Homo sapiens	76-90
15922370-3	2005	In the present study, we have examined the "anti-inflammatory effect of IT injection of neostigmine" (AI-NEO) using a standard mouse air pouch model by evaluating the effect of AI-NEO on zymosan-induced leukocyte migration and myeloperoxidase (MPO) release.	Neostigmine	88-99	myeloperoxidase	Mus musculus	227-242
16579834-1	2006	Because brain extracellular acetylcholine (ACh) levels are near detection limits in microdialysis samples, an acetylcholinesterase (AChE) inhibitor such as neostigmine is often added to microdialysis perfusates to increase ACh levels in the dialysate, a practice that raises concerns that the inhibitor might alter the results.	Neostigmine	156-167	acetylcholinesterase (Cartwright blood group)	Homo sapiens	110-130
16579834-1	2006	Because brain extracellular acetylcholine (ACh) levels are near detection limits in microdialysis samples, an acetylcholinesterase (AChE) inhibitor such as neostigmine is often added to microdialysis perfusates to increase ACh levels in the dialysate, a practice that raises concerns that the inhibitor might alter the results.	Neostigmine	156-167	acetylcholinesterase (Cartwright blood group)	Homo sapiens	132-136
16452682-10	2006	Atropine enhanced the glutamatergic EPSCs during repetitive stimulation by 25 +/- 6%; the anti-cholinesterase neostigmine reduced the train EPSCs by 37 +/- 6%.	Neostigmine	110-121	butyrylcholinesterase	Rattus norvegicus	95-109
15922370-3	2005	In the present study, we have examined the "anti-inflammatory effect of IT injection of neostigmine" (AI-NEO) using a standard mouse air pouch model by evaluating the effect of AI-NEO on zymosan-induced leukocyte migration and myeloperoxidase (MPO) release.	Neostigmine	88-99	myeloperoxidase	Mus musculus	244-247
15922370-4	2005	IT neostigmine was found to suppress both leukocyte migration and MPO degranulation in a dose dependent manner.	Neostigmine	3-14	myeloperoxidase	Mus musculus	66-69
15980188-4	2005	The AChE hydrolyzed acetylthiocholine and propyonylthiocholine, but not S-butyrylthiocholine, and the AChE-specific inhibitor neostigmine bromide competitively inhibited its activity, implying that maize AChE functions in a similar manner as the animal enzyme.	Neostigmine	126-145	GDSL esterase/lipase ACHE	Zea mays	4-8
15958263-6	2005	Neostigmine, a cholinesterase inhibitor, produced the same effect as RHC-80267 on acetylcholine-evoked relaxation.	Neostigmine	0-11	butyrylcholinesterase	Rattus norvegicus	15-29
15980188-4	2005	The AChE hydrolyzed acetylthiocholine and propyonylthiocholine, but not S-butyrylthiocholine, and the AChE-specific inhibitor neostigmine bromide competitively inhibited its activity, implying that maize AChE functions in a similar manner as the animal enzyme.	Neostigmine	126-145	GDSL esterase/lipase ACHE	Zea mays	102-106
15980188-4	2005	The AChE hydrolyzed acetylthiocholine and propyonylthiocholine, but not S-butyrylthiocholine, and the AChE-specific inhibitor neostigmine bromide competitively inhibited its activity, implying that maize AChE functions in a similar manner as the animal enzyme.	Neostigmine	126-145	GDSL esterase/lipase ACHE	Zea mays	102-106
15852394-2	2005	We report that peripheral administration of the acetylcholinesterase inhibitors tacrine, rivastigmine, neostigmine, or EN101 (an antisense oligonucleotide directed at acetylcholinesterase messenger RNA) to mice significantly attenuated the production of interleukin-1beta in the hippocampus and blood, concomitantly with the reduction in acetylcholinesterase activity.	Neostigmine	103-114	acetylcholinesterase	Mus musculus	48-68
15915024-10	2005	Neostigmine injected after cholinesterase shortened recovery further, and a train-of-four ratio of 0.8 was reached in 10-30 min.	Neostigmine	0-11	butyrylcholinesterase	Homo sapiens	27-41
15915024-13	2005	Injection of neostigmine after the administration of cholinesterase speeds up recovery.	Neostigmine	13-24	butyrylcholinesterase	Homo sapiens	53-67
12960556-2	2003	Spinal alpha 2 receptor agonist (clonidine) and cholinesterase inhibitor (neostigmine) are also active in the modulation of nociception.	Neostigmine	74-85	butyrylcholinesterase	Rattus norvegicus	7-62
15610710-4	2005	Acetylcholinesterase inhibitors such as pyridostigmine or neostigmine are the preferred first-line treatment for ocular myasthenia gravis, with mild cases requiring no additional intervention.	Neostigmine	58-69	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
15031137-2	2004	The dialysis probes were perfused with Ringer solution containing a cholinesterase inhibitor, neostigmine.	Neostigmine	94-105	butyrylcholinesterase	Rattus norvegicus	68-82
15207317-1	2004	Microinjecting the acetylcholinesterase inhibitor neostigmine into the pontine reticular formation of C57BL/6J (B6) mouse causes a rapid eye movement (REM) sleep-like state.	Neostigmine	50-61	acetylcholinesterase	Mus musculus	19-39
14619585-5	2003	RESULTS: The flinching and licking time of group NeF was shorter than that of group F, and the Fos expression of group NeF was weaker than that of group F. Pretreatment of L-Arg or L-NAME potentiated or reduced neostigmine induced responses respectively.	Neostigmine	211-222	Rho guanine nucleotide exchange factor 12	Rattus norvegicus	172-177
14619585-6	2003	CONCLUSION: Intrathecal neostigmine could induce nitric oxide release in the spinal cord, the suppression of Fos expression might be one of the antinociception mechanisms of intrathecal neostigmine in the formalin test.	Neostigmine	186-197	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	109-112
15896593-0	2005	Neostigmine-induced prolonged neuromuscular blockade in a patient with atypical pseudocholinesterase.	Neostigmine	0-11	butyrylcholinesterase	Homo sapiens	80-100
15558951-1	2004	Succinate-cytochrome c reductase was inhibited in vitro and in vivo by phenobarbitone, aminophylline and neostigmine using both 2,6-dichlorophenolindophenol (DCIP) and cytochrome c (cyt c) as substrates.	Neostigmine	105-116	cytochrome c, somatic	Homo sapiens	10-22
15558951-1	2004	Succinate-cytochrome c reductase was inhibited in vitro and in vivo by phenobarbitone, aminophylline and neostigmine using both 2,6-dichlorophenolindophenol (DCIP) and cytochrome c (cyt c) as substrates.	Neostigmine	105-116	cytochrome c, somatic	Homo sapiens	168-180
15558951-1	2004	Succinate-cytochrome c reductase was inhibited in vitro and in vivo by phenobarbitone, aminophylline and neostigmine using both 2,6-dichlorophenolindophenol (DCIP) and cytochrome c (cyt c) as substrates.	Neostigmine	105-116	cytochrome c, somatic	Homo sapiens	182-187
14736510-6	2004	The difference in quantal size in soleus muscle transmission between mutant and wild-type mice was abolished in the presence of neostigmine, an acetylcholinesterase inhibitor.	Neostigmine	128-139	acetylcholinesterase	Mus musculus	144-164
12963416-4	2003	In the presence of neostigmine (an acetylcholinesterase inhibitor), both exogenous and endogenous acetylcholine-induced catecholamine release was enhanced.	Neostigmine	19-30	acetylcholinesterase	Rattus norvegicus	35-55
12828253-10	2003	Neostigmine restored this transmission by inhibiting acetylcholinesterase, which led to increased concentrations of acetylcholine.	Neostigmine	0-11	acetylcholinesterase	Rattus norvegicus	53-73
12742187-9	2003	Neostigmine and physostigmine treatment prior to intrarectal dinitrobenzene sulfonic acid significantly attenuated macroscopic damage score, myeloperoxidase activity and smooth muscle thickness on day 5 compared to colitic Sprague-Dawley controls.	Neostigmine	0-11	myeloperoxidase	Rattus norvegicus	141-156
12742187-10	2003	Significantly greater reductions in myeloperoxidase activity were observed with physostigmine vs. neostigmine pretreatment.	Neostigmine	98-109	myeloperoxidase	Rattus norvegicus	36-51
12058442-10	2002	In the present patient with DRPLA, propofol, fentanyl, nitrous oxide, naloxone, and neostigmine administered might be factors, which could have lowered the threshold for seizure activity.	Neostigmine	84-95	atrophin 1	Homo sapiens	28-33
12712872-4	2003	Such an effect, which has been described for cholinesterase inhibitors like neostigmine and donepezil, would explain the prolonged effect of succinylcholine.	Neostigmine	76-87	butyrylcholinesterase	Homo sapiens	45-59
12605898-6	2003	Both acetylcholine and the acetylcholinesterase inhibitor neostigmine increased extracellular adenosine levels, and the effect of neostigmine was blocked by the nicotinic receptor antagonist mecamylamine.	Neostigmine	58-69	acetylcholinesterase	Rattus norvegicus	27-47
12605898-6	2003	Both acetylcholine and the acetylcholinesterase inhibitor neostigmine increased extracellular adenosine levels, and the effect of neostigmine was blocked by the nicotinic receptor antagonist mecamylamine.	Neostigmine	130-141	acetylcholinesterase	Rattus norvegicus	27-47
12522088-4	2003	Inhibition of both AChE and BChE with galanthamine (80 micro M), neostigmine (3-10 micro M), O-ethylS-2-(diisopropylamino)ethyl-methylphosphono-thioate (MTP) or phospholine decreased evoked transmitter release (20-50%).	Neostigmine	65-76	butyrylcholinesterase	Mus musculus	28-32
12242967-7	2002	For 3 months, the infant was treated with neostigmin (cholinesterase inhibitor).	Neostigmine	42-52	butyrylcholinesterase	Homo sapiens	54-68
12073883-1	2002	An enzyme inhibition biosensor, developed in our laboratory and previously used for the analysis of compounds with anticholinesterase activity (e.g. physostigmine, neostigmine, pyridostigmine nicotine and organophosphorus compounds) has now been tested for the analysis of another recently synthesized cholinesterase inhibitor, i.e. eptastigmine.	Neostigmine	164-175	butyrylcholinesterase	Homo sapiens	119-133
11454976-8	2001	One membrane was perfused with the acetylcholinesterase inhibitor neostigmine, while the other was perfused with the vehicle.	Neostigmine	66-77	acetylcholinesterase (Cartwright blood group)	Homo sapiens	35-55
11903079-4	2002	METHODS: The acetylcholinesterase inhibitor neostigmine was encapsulated into multilamellar lipid vesicles composed of phosphocholine and cholesterol.	Neostigmine	44-55	acetylcholinesterase	Mus musculus	13-33
11605898-2	2001	In the current study, we determined the antiallodynic effect of intrathecal injection of an acetylcholinesterase inhibitor, neostigmine, in a rat model of diabetic neuropathic pain.	Neostigmine	124-135	acetylcholinesterase	Rattus norvegicus	92-112
11521162-10	2001	Inhibitors of cholinesterase (physostigmine, neostigmine; 3 microM) facilitated the efflux of acetylcholine about sixfold, and a combination of both (+)-tubocurarine (30 microM) and scopolamine (1 microM) halved the enhancing effect.	Neostigmine	45-56	butyrylcholinesterase	Homo sapiens	14-28
11668032-1	2001	The cholinesterase inhibitor neostigmine indirectly stimulates muscarinic M(1)/M(2)/M(3) receptors, thereby reducing colonic distension in acute colonic pseudo-obstruction.	Neostigmine	29-40	butyrylcholinesterase	Homo sapiens	4-18
11313435-5	2001	When the solution contained 10 microM neostigmine (NEO) 3000 stimuli reduced [integral]MEPCs by 60 %, because with acetylcholinesterase (AChE) inhibited, [integral]MEPC size is more sensitive to changes in acetylcholine (ACh) content.	Neostigmine	38-49	acetylcholinesterase (Cartwright blood group)	Homo sapiens	115-135
11484778-7	2001	Addition of atropine, a muscarinic receptor antagonist, to the dialysis medium containing neostigmine attenuated the increase of Fos-IR and suppressed the neostigmine-induced responses in body temperature.	Neostigmine	90-101	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	129-132
11313435-5	2001	When the solution contained 10 microM neostigmine (NEO) 3000 stimuli reduced [integral]MEPCs by 60 %, because with acetylcholinesterase (AChE) inhibited, [integral]MEPC size is more sensitive to changes in acetylcholine (ACh) content.	Neostigmine	38-49	acetylcholinesterase (Cartwright blood group)	Homo sapiens	137-141
11313435-5	2001	When the solution contained 10 microM neostigmine (NEO) 3000 stimuli reduced [integral]MEPCs by 60 %, because with acetylcholinesterase (AChE) inhibited, [integral]MEPC size is more sensitive to changes in acetylcholine (ACh) content.	Neostigmine	51-54	acetylcholinesterase (Cartwright blood group)	Homo sapiens	115-135
11313435-5	2001	When the solution contained 10 microM neostigmine (NEO) 3000 stimuli reduced [integral]MEPCs by 60 %, because with acetylcholinesterase (AChE) inhibited, [integral]MEPC size is more sensitive to changes in acetylcholine (ACh) content.	Neostigmine	51-54	acetylcholinesterase (Cartwright blood group)	Homo sapiens	137-141
11226704-0	2001	P75-expressing elements are necessary for anti-allodynic effects of spinal clonidine and neostigmine.	Neostigmine	89-100	nerve growth factor receptor	Rattus norvegicus	0-3
11172789-0	2001	The elevation of plasma adrenocorticotrophic hormone and expression of c-Fos in hypothalamic paraventricular nucleus by microinjection of neostigmine into the hippocampus in rats: comparison with acute stress responses.	Neostigmine	138-149	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	71-76
11172789-3	2001	The patterns of expression of Fos-ir in the PVN after microinjection of neostigmine into the hippocampus were not different from those seen in the two stressful situations.	Neostigmine	72-83	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	30-33
11330337-4	2001	A series of compounds, representative of the principal classes of acetylcholinesterase inhibitors, displaced [3H]-oxotremorine-M binding with high-to-moderate potency (ambenonium>neostigmine=pyridostigmine=tacrine>physostigmine> edrophonium=galanthamine>desoxypeganine) whereas only ambenonium and tacrine displaced [3H]-quinuclinidyl benzilate binding.	Neostigmine	182-193	acetylcholinesterase	Rattus norvegicus	66-86
11330337-8	2001	Moreover, the rank order for potency in inhibiting acetylcholinesterase (ambenonium>neostigmine=physostigmine =tacrine>pyridostigmine=edrophonium=galanthamine >desoxypeganine>parathion>gramine) indicated that the most effective inhibitors of acetylcholinesterase also displaced [3H]-oxotremorine-M to the greatest extent.	Neostigmine	87-98	acetylcholinesterase	Rattus norvegicus	51-71
11181580-5	2001	One probe was perfused with the AChE inhibitor neostigmine (10 microM); the adjacent membrane was perfused with the vehicle (Ringer solution).	Neostigmine	47-58	acetylcholinesterase (Cartwright blood group)	Homo sapiens	32-36
11951576-0	2001	Rise in plasma leptin levels after stimulation of hypothalamic cholinoceptive neurons by neostigmine in rats.	Neostigmine	89-100	leptin	Rattus norvegicus	15-21
11951576-2	2001	The administration of neostigmine (5 x 10(-9) or 5 x 10(-8) mol) increased plasma leptin levels 3-6 h after stimulation in a dose-dependent manner, while intravenous injection of neostigmine (5 x 10(-8) mol) had no effect.	Neostigmine	22-33	leptin	Rattus norvegicus	82-88
11951576-3	2001	Atropine (5 x 10(-8) mol) concomitantly injected with neostigmine (5 x 10(-8) mol) prevented neostigmine-induced increase in plasma leptin.	Neostigmine	54-65	leptin	Rattus norvegicus	132-138
11951576-3	2001	Atropine (5 x 10(-8) mol) concomitantly injected with neostigmine (5 x 10(-8) mol) prevented neostigmine-induced increase in plasma leptin.	Neostigmine	93-104	leptin	Rattus norvegicus	132-138
11951576-4	2001	The expression of leptin messenger ribonucleic acid (mRNA) in epididymal white adipose tissue was significantly increased at 4 and 6 h after neostigmine injection compared with that before the injection.	Neostigmine	141-152	leptin	Rattus norvegicus	18-24
11073873-6	2000	The results show an increase in the firing rate, T:(IBAT), T:(C) and oxygen consumption after the neostigmine injection.	Neostigmine	98-109	solute carrier family 10 member 2	Rattus norvegicus	52-56
11031092-4	2000	In MG patients, the open-loop gains of OKN increased significantly after the intramuscular injection of an acetylcholinesterase inhibitor, neostigmine, while the closed-loop OKN gains were not significantly changed.	Neostigmine	139-150	acetylcholinesterase (Cartwright blood group)	Homo sapiens	107-127
10677634-1	2000	Using in vivo microdialysis in freely moving rats, we show that the addition to the dialysis perfusion fluid of the acetylcholinesterase inhibitor neostigmine influences the decarboxylation of levodopa (L-dopa).	Neostigmine	147-158	acetylcholinesterase	Rattus norvegicus	116-136
10826417-3	2000	Neostigmine enhances excitatory parasympathetic activity by competing with acetylcholine for attachment to acetylcholinesterase at sites of cholinergic transmission and enhancing cholinergic action.	Neostigmine	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	107-127
10657037-3	2000	Dialysis was performed in the presence of Neostigmine (0.5 microM), an acetylcholinesterase inhibitor, in prefrontal cortex or hippocampus of freely moving rats.	Neostigmine	42-53	acetylcholinesterase	Rattus norvegicus	71-91
11819669-11	2000	Duodenal damage induced by acid perfusion (100mM HCl for 4h) in the presence of indomethacin was significantly prevented by nizatidine and neostigmine, at the doses that increased the HCO(3)(-)secretion.CONCLUSION:Nizatidine stimulates duodenal HCO(3)(-) secretion, in both vagal dependent and atropine sensitive manners, and the action is associated with the anti-AChE activity of this agent.	Neostigmine	139-150	acetylcholinesterase	Rattus norvegicus	365-369
10952694-2	2000	Both acetylcholine (100 microM) and the cholinesterase inhibitor neostigmine (100 microM) inhibited the stimulation-induced (S-I) outflow of radioactivity but in the presence of atropine (0.3 microM) an enhancement was seen, which may be indicative of facilitatory nicotinic receptors.	Neostigmine	65-76	butyrylcholinesterase	Mus musculus	40-54
9865858-6	1998	Such relaxant effects of H2O2 were enhanced, significantly, by an acetylcholinesterase antagonist, neostigmine.	Neostigmine	99-110	acetylcholinesterase	Canis lupus familiaris	66-86
11913717-4	2000	The purpose of this study is to explain the protective effects of neostigmine against paraoxon toxicity by suppressing CYP3A and hence decreasing formation of toxic metabolite, paraoxon by neostigmine.	Neostigmine	66-77	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	119-124
11913717-8	2000	The above data suggested that the formation of paraoxon was inhibited in rats pretreated with neostigmine by inhibiting CYP3A.	Neostigmine	94-105	cytochrome P450, family 3, subfamily a, polypeptide 62	Rattus norvegicus	120-125
10585525-4	1999	Microdialysis was performed with a Ringer containing low concentrations (0.01 microM) of the acetylcholinesterase inhibitor, neostigmine.	Neostigmine	125-136	acetylcholinesterase (Cartwright blood group)	Homo sapiens	93-113
10069522-6	1999	Although no cholinergic agonists have been tested for safety in humans, the cholinesterase inhibitor, neostigmine, has undergone such testing, and produces analgesia to experimental, acute postoperative, and chronic pain.	Neostigmine	102-113	butyrylcholinesterase	Homo sapiens	76-90
9806710-0	1998	The effects of donepezil and neostigmine in a patient with unusual pseudocholinesterase activity.	Neostigmine	29-40	butyrylcholinesterase	Homo sapiens	67-87
10499750-1	1999	BACKGROUND AND OBJECTIVES: The acetylcholinesterase inhibitor neostigmine has shown peripherally mediated analgesic action in recent preclinical and clinical studies.	Neostigmine	62-73	acetylcholinesterase (Cartwright blood group)	Homo sapiens	31-51
10433996-2	1999	Based on dose-response experiments, we microdialyzed a 0.1 mM solution of the acetylcholinesterase inhibitor neostigmine into the L7 level of the dorsal horn of anesthetized cats to determine its effects on the mean arterial blood pressure (MAP) and heart rate (HR) responses to static muscle contraction or passive stretch.	Neostigmine	109-120	acetylcholinesterase	Felis catus	78-98
9952157-12	1999	CONCLUSIONS: These experiments suggest that intrathecal edrophonium or neostigmine produces an antagonism on touch-evoked allodynia at the spinal level in a rat model of neuropathic pain and that the antiallodynic action of cholinesterase inhibitors is probably mediated by a spinal muscarinic system, especially at the M1 receptor subtype.	Neostigmine	71-82	butyrylcholinesterase	Rattus norvegicus	224-238
10094138-1	1999	The effect of the cholinesterase inhibitor neostigmine on hippocampal noradrenaline (NA) release was studied using in vivo microdialysis.	Neostigmine	43-54	butyrylcholinesterase	Homo sapiens	18-32
10094138-7	1999	The fact that neostigmine is able to enhance both cholinergic and noradrenergic neurotransmission may help to understand the beneficial effect of cholinesterase inhibitors in Alzheimer"s disease.	Neostigmine	14-25	butyrylcholinesterase	Homo sapiens	146-160
10051150-6	1999	Neostigmine potentiated the OA-induced bronchoconstriction in vivo and airway muscle contraction in vitro of BP2 mice.	Neostigmine	0-11	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	28-30
11286343-4	1998	The mPRF was microinjected with 0.25 ml saline, carbachol (4.0 microg), neostigmine (6.7 microg), or morphine sulfate (14.7 microg), and TFL measures were obtained in response to radiant heat.	Neostigmine	72-83	Spi-C transcription factor (Spi-1/PU.1 related)	Mus musculus	4-8
9697967-5	1998	Three cholinesterase inhibitors, physostigmine, neostigmine, and edrophonium, suppressed the activity of the leading edges of the extending axons (the nerve growth cones) dose dependently.	Neostigmine	48-59	butyrylcholinesterase	Gallus gallus	6-20
11498913-4	1998	The probe was perfused at a rate of 1 microL/min with Ringer"s solution which contained 10 mumol/L (for anesthetized rats) or 1 mumol/L (for freely moving rats) neostigmine, a reversible cholinesterase inhibitor, to elevate ACh level in microdialysate.	Neostigmine	161-172	butyrylcholinesterase	Rattus norvegicus	187-201
9729629-11	1998	Acetylcholinesterase (AChE) may not be involved in SP degradation since Ca2+ responses evoked by SP were unchanged in the presence of the cholinesterase inhibitor neostigmine.	Neostigmine	163-174	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
9729629-11	1998	Acetylcholinesterase (AChE) may not be involved in SP degradation since Ca2+ responses evoked by SP were unchanged in the presence of the cholinesterase inhibitor neostigmine.	Neostigmine	163-174	tachykinin precursor 1	Homo sapiens	97-99
9605686-5	1998	The ability of neostigmine to inhibit cholinesterase activity in vitro was also measured.	Neostigmine	15-26	cholinesterase	Sus scrofa	38-52
9605686-11	1998	Neostigmine inhibited cholinesterase activity in a log-dose-dependent manner.	Neostigmine	0-11	cholinesterase	Sus scrofa	22-36
9507142-6	1998	Both neostigmine and DFP applied after AChE inhibition by DFP sometimes elicited a transient response.	Neostigmine	5-16	acetylcholinesterase	Rattus norvegicus	39-43
9696463-7	1998	Attenuation of afferent nerve activity was not mimicked by the anticholinergic glycopyrrolate; the cholinesterase inhibitor neostigmine did not attenuate the effect of IMI on responses to noxious CRD.	Neostigmine	124-135	butyrylcholinesterase	Rattus norvegicus	99-113
9489729-2	1998	Systemic administration of d-amphetamine (2 or 10 mg/kg) increased the striatal output of ACh when the AChE inhibitor neostigmine (0.1 microM) was present in the perfusion fluid.	Neostigmine	118-129	acetylcholinesterase (Cartwright blood group)	Homo sapiens	103-107
9777037-3	1998	The activity of the enzyme acetylcholinesterase was also evaluated in diverse structures of the central nervous system after the intracerebral administration of neostigmine.	Neostigmine	161-172	acetylcholinesterase	Rattus norvegicus	27-47
9477052-11	1998	CONCLUSIONS: Intra-articular injection of the acetylcholinesterase inhibitor neostigmine produced a moderate but significant analgesic effect.	Neostigmine	77-88	acetylcholinesterase (Cartwright blood group)	Homo sapiens	46-66
9777037-10	1998	Because the used route of administration of neostigmine, a greater degree of inhibition of the hypothalamic acetylcholinesterase is observed, suggesting then that the hypothalamic structures could be involved in the cardiovascular effects induced by the intracerebral administration of the anticholinesterase.	Neostigmine	44-55	acetylcholinesterase	Rattus norvegicus	108-128
9566772-10	1998	Nevertheless, VIP and NaNP do also cause relaxation of preparations preincubated with neostigmine.	Neostigmine	86-97	vasoactive intestinal peptide	Homo sapiens	14-17
9286623-2	1997	The protective effect of amylin was inhibited by pretreatment with capsicin as well as CGRP-(8-37), a calcitonin gene-related peptide (CGRP) and amylin receptor antagonist, and was significantly reduced by domperidone, a dopamine D2 receptor antagonist, or neostigmine, an inhibitor of acetylcholinesterase.	Neostigmine	257-268	islet amyloid polypeptide	Homo sapiens	25-31
9405519-4	1997	The effects of the afferent stimulus were greatly enhanced in CA1 neurons exposed to the catalytic AChE inhibitors neostigmine, physostigmine, or 9-amino-1,2,3, 4-tetrahydro-acridine.	Neostigmine	115-126	carbonic anhydrase 1	Rattus norvegicus	62-65
9405519-4	1997	The effects of the afferent stimulus were greatly enhanced in CA1 neurons exposed to the catalytic AChE inhibitors neostigmine, physostigmine, or 9-amino-1,2,3, 4-tetrahydro-acridine.	Neostigmine	115-126	acetylcholinesterase	Rattus norvegicus	99-103
9430419-1	1997	The acetylcholinesterase inhibitor neostigmine (2 microg) was microinjected into the lateral cerebral ventricle (i.c.v.)	Neostigmine	35-46	acetylcholinesterase	Rattus norvegicus	4-24
12162322-9	1998	Furthermore, the asymmetric distribution of immunoreacted IAA-inositol synthase was inhibited by neostigmine bromide, AChE inhibitor.	Neostigmine	97-116	GDSL esterase/lipase ACHE	Zea mays	118-122
9322468-8	1997	IMPLICATIONS: Spinal muscarinic agonists, such as carbachol and the cholinesterase inhibitor neostigmine, induce a potent analgesia in the rat.	Neostigmine	93-104	butyrylcholinesterase	Rattus norvegicus	68-82
9374188-9	1997	These results indicate that neostigmine and carbaryl directly block the nicotinic AChR channel.	Neostigmine	28-39	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	82-86
9286623-2	1997	The protective effect of amylin was inhibited by pretreatment with capsicin as well as CGRP-(8-37), a calcitonin gene-related peptide (CGRP) and amylin receptor antagonist, and was significantly reduced by domperidone, a dopamine D2 receptor antagonist, or neostigmine, an inhibitor of acetylcholinesterase.	Neostigmine	257-268	calcitonin related polypeptide alpha	Homo sapiens	87-91
9253944-1	1997	To investigate the mutual dependence of calcitonin gene-related peptide (CGRP) and acetylcholine release, we examined the effect of a cholinesterase inhibitor neostigmine on the release of CGRP-like immunoreactivity in rat phrenic nerve-hemidiaphragm muscle preparation, and conversely, the effect of CGRP on [3H]acetylcholine release from motor nerve terminals loaded with [3H]choline in the same preparations of mice.	Neostigmine	159-170	butyrylcholinesterase	Rattus norvegicus	134-148
9279814-9	1997	The desensitization of ACh receptors potentiated by proadifen, prevented completely the 6- to 8-fold prolongation of EPC which was induced by neostigmine inhibition of synaptic AChE.	Neostigmine	142-153	acetylcholinesterase (Cartwright blood group)	Homo sapiens	177-181
9253944-1	1997	To investigate the mutual dependence of calcitonin gene-related peptide (CGRP) and acetylcholine release, we examined the effect of a cholinesterase inhibitor neostigmine on the release of CGRP-like immunoreactivity in rat phrenic nerve-hemidiaphragm muscle preparation, and conversely, the effect of CGRP on [3H]acetylcholine release from motor nerve terminals loaded with [3H]choline in the same preparations of mice.	Neostigmine	159-170	calcitonin-related polypeptide alpha	Rattus norvegicus	189-193
9253944-1	1997	To investigate the mutual dependence of calcitonin gene-related peptide (CGRP) and acetylcholine release, we examined the effect of a cholinesterase inhibitor neostigmine on the release of CGRP-like immunoreactivity in rat phrenic nerve-hemidiaphragm muscle preparation, and conversely, the effect of CGRP on [3H]acetylcholine release from motor nerve terminals loaded with [3H]choline in the same preparations of mice.	Neostigmine	159-170	calcitonin-related polypeptide alpha	Rattus norvegicus	189-193
9253944-3	1997	Neostigmine (0.1-0.3 microM) enhanced the resting release of CGRP-like immunoreactivity in a concentration-dependent manner, whereas it depressed the nerve-evoked release of CGRP-like immunoreactivity.	Neostigmine	0-11	calcitonin-related polypeptide alpha	Rattus norvegicus	61-65
9253944-3	1997	Neostigmine (0.1-0.3 microM) enhanced the resting release of CGRP-like immunoreactivity in a concentration-dependent manner, whereas it depressed the nerve-evoked release of CGRP-like immunoreactivity.	Neostigmine	0-11	calcitonin-related polypeptide alpha	Rattus norvegicus	174-178
8955970-6	1996	The plasma cholinesterase activity (PCHE) after neostigmine decreased from 6596 to 1959 U.L-1 (P < 0.001) but there was no change after edrophonium (6140 to 6396 U.L-1).	Neostigmine	48-59	butyrylcholinesterase	Homo sapiens	11-25
11536808-6	1997	The hydrolytic activity was inhibited 80 to 90% by neostigmine, an inhibitor of AChE.	Neostigmine	51-62	GDSL esterase/lipase ACHE	Zea mays	80-84
12436684-2	1997	A sharp increase of mEPC frequency (not less than approximately 50 per sec) was followed by an obvious fall in both their amplitude and acceleration of decay only in the presence of 3 microM prostigmine (acetylcholinesterase inhibitor) and 5 microM proadiphene, these agents promoting a desensitization of cholinergic postsynaptic membrane.	Neostigmine	191-202	transcription factor 21	Mus musculus	20-24
8987799-5	1997	A second series of experiments demonstrated that mPRF microinjection of NLA significantly reduced the amount of REM sleep and the REM sleep-like state caused by mPRF injection of the acetylcholinesterase inhibitor neostigmine.	Neostigmine	214-225	Spi-C transcription factor (Spi-1/PU.1 related)	Mus musculus	49-53
8987799-5	1997	A second series of experiments demonstrated that mPRF microinjection of NLA significantly reduced the amount of REM sleep and the REM sleep-like state caused by mPRF injection of the acetylcholinesterase inhibitor neostigmine.	Neostigmine	214-225	Spi-C transcription factor (Spi-1/PU.1 related)	Mus musculus	161-165
8987799-5	1997	A second series of experiments demonstrated that mPRF microinjection of NLA significantly reduced the amount of REM sleep and the REM sleep-like state caused by mPRF injection of the acetylcholinesterase inhibitor neostigmine.	Neostigmine	214-225	acetylcholinesterase (Cartwright blood group)	Homo sapiens	183-203
8987799-7	1997	Injection of NLA into the mPRF before neostigmine injection also blocked the ability of neostigmine to decrease respiratory rate during the REM sleep-like state.	Neostigmine	88-99	Spi-C transcription factor (Spi-1/PU.1 related)	Mus musculus	26-30
8997608-3	1996	Acetylcholine measurements were conducted in the presence of 10 nmol/l of the acetylcholinesterase inhibitor neostigmine in the microdialysis perfusate.	Neostigmine	109-120	acetylcholinesterase	Rattus norvegicus	78-98
8698109-5	1996	Pre-treatment with neostigmine blocked the effect of amylin when it was centrally injected, while the effect of amylin given peripherally was partially reduced.	Neostigmine	19-30	islet amyloid polypeptide	Rattus norvegicus	53-59
8863503-7	1996	The cholinesterase inhibitor neostigmine decreased [3H]ACh release at 3 Hz but not at 0.1 Hz; in the presence of atropine, neostigmine potentiated [3H]ACh release, an effect blocked by mecamylamine.	Neostigmine	29-40	butyrylcholinesterase	Homo sapiens	4-18
8863503-7	1996	The cholinesterase inhibitor neostigmine decreased [3H]ACh release at 3 Hz but not at 0.1 Hz; in the presence of atropine, neostigmine potentiated [3H]ACh release, an effect blocked by mecamylamine.	Neostigmine	123-134	butyrylcholinesterase	Homo sapiens	4-18
9044164-5	1996	Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.	Neostigmine	150-161	butyrylcholinesterase	Rattus norvegicus	24-27
9044164-5	1996	Inhibitory constants of ChE inhibitors to bovine erythrocyte AChE determined in vitro were 2019, 276, 26, and 3.7 nM for edrophonium, pyridostigmine, neostigmine, and ambenonium, respectively.	Neostigmine	150-161	acetylcholinesterase	Bos taurus	61-65
8864531-3	1996	In the process of nicotinic AChR desensitization, the enhancing role of calcitonin gene-related peptide (CGRP) on the non-contractile Ca2(+)-induced depression of contractile Ca2+ mobilization was investigated by measurement of Ca2(+)-aequorin luminescence in the presence of neostigmine (0.1 microM).	Neostigmine	276-287	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	72-103
8864531-3	1996	In the process of nicotinic AChR desensitization, the enhancing role of calcitonin gene-related peptide (CGRP) on the non-contractile Ca2(+)-induced depression of contractile Ca2+ mobilization was investigated by measurement of Ca2(+)-aequorin luminescence in the presence of neostigmine (0.1 microM).	Neostigmine	276-287	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	105-109
8807181-1	1996	PURPOSE: The bradycardia produced by neostigmine and edrophonium was examined according to its relation to cholinesterase inhibition and to its sensitivity to block by muscarinic receptor antagonists.	Neostigmine	37-48	butyrylcholinesterase	Felis catus	107-121
8807181-8	1996	RESULTS: Neostigmine produced a dose-dependent decrease in cholinesterase activity which reached a plateau at a cumulative dose of 0.16 mg.kg-1 (ED50 0.009 +/- 0.003 mg.kg-1).	Neostigmine	9-20	butyrylcholinesterase	Felis catus	59-73
8807181-9	1996	Neostigmine produced a dose-dependent decrease in heart rate with the dose-response relationship (ED50 0.1 +/- 0.01 mg.kg-1; P = 0.0006) shifted to the right of that for the inhibition of cholinesterase activity.	Neostigmine	0-11	butyrylcholinesterase	Felis catus	188-202
8638849-15	1996	Bovine pseudocholinesterase and human plasma cholinesterase equally reversed the effects of succinylcholine but acetylcholinesterase did not, whereas the addition of 10 micrograms/ml neostigmine to the enzymes inhibited the reversal of succinylcholine.	Neostigmine	183-194	butyrylcholinesterase	Homo sapiens	13-27
8551354-1	1996	Microinjections of the cholinergic receptor agonist nicotine and the cholinesterase inhibitor neostigmine were made into the ventral tegmental area (VTA) of urethane-anesthetized rats, and dopamine (DA) efflux in the nucleus accumbens was measured using in vivo chronoamperometry.	Neostigmine	94-105	butyrylcholinesterase	Rattus norvegicus	69-83
8584207-1	1995	Induction of c-Fos expression in the supraoptic nucleus (SON) of the rat hypothalamus by endogenous acetylcholine was examined by microinfusion of neostigmine, a cholinesterase inhibitor, into the nucleus to locally accumulate the spontaneously released acetylcholine from the cholinergic terminals in the SON.	Neostigmine	147-158	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	13-18
8822186-4	1995	Naloxone, an opioid antagonist, and neostigmine, an acetylcholinesterase inhibitor, are thought to restore motility of the large colon in cases of large colon impaction in the horse.	Neostigmine	36-47	acetylcholinesterase	Equus caballus	52-72
8613768-1	1995	We used in vivo microdialysis to investigate the effects of local perfusion with the AChE inhibitor neostigmine on the basal and haloperidol evoked increase in dialysate dopamine levels in the dorsolateral and fundus striata of the bilaterally implanted halothane anaesthetized rat.	Neostigmine	100-111	acetylcholinesterase	Rattus norvegicus	85-89
7486038-9	1995	Plasma cholinesterase activity was decreased to 29% of control at 15 min and remained at approximately 60% of the control after neostigmine administration.	Neostigmine	128-139	butyrylcholinesterase	Homo sapiens	7-21
8584207-3	1995	Fos-like immunoreactivity was manifested in both the vasopressin neurons and oxytocin neurons following the microinfusion of neostigmine.	Neostigmine	125-136	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	0-3
8584207-3	1995	Fos-like immunoreactivity was manifested in both the vasopressin neurons and oxytocin neurons following the microinfusion of neostigmine.	Neostigmine	125-136	arginine vasopressin	Rattus norvegicus	53-64
7605023-8	1995	Neostigmine decreased plasma cholinesterase activity and increased plasma concentrations of the trans-trans and cis-trans stereoisomers of mivacurium (P < 0.05).	Neostigmine	0-11	butyrylcholinesterase	Homo sapiens	29-43
7745844-6	1995	Neostigmine, an AChE inhibitor, dose-dependently enhanced the small intestinal propulsion and the proximal and the distal colonic propulsion at 0.3 to 10 mg/kg, p.o., whereas it delayed the gastric emptying at 10 mg/kg, p.o.	Neostigmine	0-11	acetylcholinesterase	Rattus norvegicus	16-20
7570638-5	1995	Application of 1 microM neostigmine 1 hr after 3,4-DAP led to a further potentiation of twitch tension, but this action lasted for < 20 min.	Neostigmine	24-35	death-associated protein	Rattus norvegicus	51-54
7856900-1	1995	BACKGROUND: The spinal delivery of the cholinesterase inhibitor neostigmine yields analgesia in rats and augments the analgesic effects of alpha 2 agonists in sheep.	Neostigmine	64-75	butyrylcholinesterase	Rattus norvegicus	39-53
7891028-0	1995	Effect of actively immunizing sheep against growth hormone-releasing hormone or somatostatin on spontaneous pulsatile and neostigmine-induced growth hormone secretion.	Neostigmine	122-133	somatotropin	Ovis aries	44-58
7589397-11	1995	After neostigmine, there was a significant increase in MIP in patients with generalized myasthenia gravis and a trend towards an increased MEP.	Neostigmine	6-17	cathepsin L	Homo sapiens	139-142
7810679-11	1994	Studies in intact intrapulmonary lobar arteries showed that these vessels had cholinesterase activity comparable with that found in intact trachealis muscle and that neostigmine (10 nM to 10 microM) caused concentration-dependent inhibition of enzyme activity.	Neostigmine	166-177	cholinesterase	Oryctolagus cuniculus	78-92
7971167-5	1994	We studied the effects of acetylcholinesterase (AChE) inhibition with neostigmine, diisopropyl fluorophosphate (DFP) and fasciculin-2.	Neostigmine	70-81	acetylcholinesterase	Mus musculus	26-46
7883027-1	1994	When acetylcholinesterase was inhibited by neostigmine, SK&F 96365 (1-(beta-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenethyl)-1H-imidazole hydrochloride) at 10 microM caused no effect on the amplitude of single endplate potentials (e.p.p.s) but shortened the decay time in mouse phrenic nerve-diaphragm preparations.	Neostigmine	43-54	acetylcholinesterase	Mus musculus	5-25
7723214-4	1994	The IC50 values of neostigmine for AChE and BuChE were 3.6 x 10(-8) M and 1.9 x 10(-7) M, respectively.	Neostigmine	19-30	acetylcholinesterase	Cavia porcellus	35-39
7723214-4	1994	The IC50 values of neostigmine for AChE and BuChE were 3.6 x 10(-8) M and 1.9 x 10(-7) M, respectively.	Neostigmine	19-30	cholinesterase	Cavia porcellus	44-49
7723214-7	1994	On the other hand, the AChE inhibition by neostigmine was non-competitive when the enzyme was preincubated with this inhibitor for 2 min prior to the addition of the substrate, and it was nearly competitive when the enzyme, the inhibitor and the substrate were incubated simultaneously.	Neostigmine	42-53	acetylcholinesterase	Cavia porcellus	23-27
7869618-3	1994	The IC50 of itopride with AChE (2.04 +/- 0.27 microM) was, however, 100-fold less than that with BuChE, whereas in the case of neostigmine with AChE (11.3 +/- 3.4 nM), it was 10-fold less.	Neostigmine	127-138	acetylcholinesterase	Cavia porcellus	144-148
7869618-4	1994	The recovery of AChE activity inhibited by 10(-7) M neostigmine was partial, but that inhibited by up to 3 x 10(-5) M itopride was complete when the reaction mixture was subjected to ultrafiltration.	Neostigmine	52-63	acetylcholinesterase	Cavia porcellus	16-20
7820671-0	1994	Adrenocorticotropin and growth hormone secretions after intracerebroventricular administration of neostigmine in rats: their relationships to hypothalamic monoaminergic neuronal activities.	Neostigmine	98-109	gonadotropin releasing hormone receptor	Rattus norvegicus	24-38
7971167-5	1994	We studied the effects of acetylcholinesterase (AChE) inhibition with neostigmine, diisopropyl fluorophosphate (DFP) and fasciculin-2.	Neostigmine	70-81	acetylcholinesterase	Mus musculus	48-52
7983588-2	1994	The presence of either NaCl or LiCl in the donor solution caused significant fluxes of neostigmine, with permeability coefficients (Kp"s) in the range of 10(-6) cm min-1.	Neostigmine	87-98	CD59 molecule (CD59 blood group)	Homo sapiens	164-169
7834577-4	1994	Systemically administered scopolamine greatly increased the PPT stimulation evoked cortical release of ACh when the cortical probe was perfused with the cholinesterase inhibitor neostigmine.	Neostigmine	178-189	butyrylcholinesterase	Rattus norvegicus	153-167
7978176-14	1994	As TH1 is between 1% and 10% 25 to 29 min before TOF ratio 0.70 is reached during spontaneous recovery, the optimal level of neuromuscular blockade for neostigmine administration in atracurium blockade is when TH1 is between 1% and 10%.	Neostigmine	152-163	negative elongation factor complex member C/D	Homo sapiens	3-6
7978176-14	1994	As TH1 is between 1% and 10% 25 to 29 min before TOF ratio 0.70 is reached during spontaneous recovery, the optimal level of neuromuscular blockade for neostigmine administration in atracurium blockade is when TH1 is between 1% and 10%.	Neostigmine	152-163	negative elongation factor complex member C/D	Homo sapiens	210-213
7978176-15	1994	CONCLUSION: Reversal time can be predicted as 27.3 min - (0.89 x prereversal time (min), and the optimal time of neostigmine administration in atracurium blockade appears to be when TH1 is 1%-10%.	Neostigmine	113-124	negative elongation factor complex member C/D	Homo sapiens	182-185
8045845-7	1994	Physostigmine and neostigmine did not alter resting release of CGRP from rat trachea, although exogenous (10(-5) M) ACh-induced CGRP release was enhanced in the presence of neostigmine, suggesting minimal tonic cholinergic activity in this model.	Neostigmine	173-184	calcitonin-related polypeptide alpha	Rattus norvegicus	128-132
7967226-5	1994	Neostigmine, an AChE inhibitor, enhanced the motor activity at 0.03 and 0.1 mg/kg, i.v.	Neostigmine	0-11	acetylcholinesterase	Canis lupus familiaris	16-20
8264551-3	1993	Present results show that AE-2 decreases the rate of inhibition of FBS AChE by the positively charged organophosphate amiton-p-toluene sulfonate and the positively charged carbamates pyridostigmine and neostigmine but accelerates inhibition of FBS AChE by the neutral organophosphates paraoxon and diisopropylfluorophosphate.	Neostigmine	202-213	solute carrier family 4 member 2	Homo sapiens	26-30
8206111-6	1994	Pyridostigmine, neostigmine and physostigmine induced a significant GH increase (peak vs. basal levels, mean +/- S.E.	Neostigmine	16-27	growth hormone 1	Homo sapiens	68-70
8019748-19	1994	Physostigmine, neostigmine, tacrine and DFP (all at 30 microM) each produced near-total (> 96%) inhibition of AChE activity.	Neostigmine	15-26	acetylcholinesterase	Rattus norvegicus	113-117
8057530-6	1994	Neostigmine, whose AChE inhibitory activity is equipotent to that of KW-5092, did not evoke ACh release even at 3 x 10(-6) M, indicating that the ACh release by KW-5092 is not due to its AChE inhibitory activity.	Neostigmine	0-11	acetylcholinesterase	Cavia porcellus	19-23
8264551-3	1993	Present results show that AE-2 decreases the rate of inhibition of FBS AChE by the positively charged organophosphate amiton-p-toluene sulfonate and the positively charged carbamates pyridostigmine and neostigmine but accelerates inhibition of FBS AChE by the neutral organophosphates paraoxon and diisopropylfluorophosphate.	Neostigmine	202-213	acetylcholinesterase (Cartwright blood group)	Homo sapiens	71-75
8474626-3	1993	However, local administration of the cholinesterase inhibitors neostigmine, physostigmine or heptyl-physostigmine through the dialysis probe elevated acetylcholine above the detection limit.	Neostigmine	63-74	butyrylcholinesterase	Rattus norvegicus	37-51
8308673-7	1993	VIP infusion at 12 ng/min and 480 ng/min completely inhibited the increased intensity of contraction at neostigmine doses of 0.10 and 0.15 mg, respectively.	Neostigmine	104-115	VIP peptides	Oryctolagus cuniculus	0-3
8223896-2	1993	The contractile responses to endothelin-1 were attenuated by atropine and augmented by neostigmine in the inferior caval and portal veins, but were not affected by either agent in the jugular vein.	Neostigmine	87-98	endothelin 1	Canis lupus familiaris	29-41
7694432-5	1993	Pretreatment with neostigmine elevated basal plasma GH levels and partially inhibited GAL-induced GH secretion.	Neostigmine	18-29	gonadotropin releasing hormone receptor	Rattus norvegicus	52-54
7694432-5	1993	Pretreatment with neostigmine elevated basal plasma GH levels and partially inhibited GAL-induced GH secretion.	Neostigmine	18-29	galanin and GMAP prepropeptide	Rattus norvegicus	86-89
7694432-5	1993	Pretreatment with neostigmine elevated basal plasma GH levels and partially inhibited GAL-induced GH secretion.	Neostigmine	18-29	gonadotropin releasing hormone receptor	Rattus norvegicus	98-100
7694432-8	1993	Neostigmine-induced GH secretion was partially inhibited by yohimbine and phenoxybenzamine.	Neostigmine	0-11	gonadotropin releasing hormone receptor	Rattus norvegicus	20-22
8095014-0	1993	Neostigmine stimulates growth hormone-releasing hormone release into hypophysial portal blood of conscious sheep.	Neostigmine	0-11	LOC780526	Ovis aries	23-55
8095014-1	1993	GH secretion is stimulated by the administration of cholinesterase inhibitors (such as pyridostigmine and neostigmine) in several species, including man.	Neostigmine	106-117	butyrylcholinesterase	Homo sapiens	52-66
8441002-3	1993	Enhancing extracellular concentrations of ACh in the substantia nigra by intranigral infusions of the cholinesterase inhibitor neostigmine also resulted in an increase in the chronoamperometric signal corresponding to DA overflow in the striatum.	Neostigmine	127-138	butyrylcholinesterase	Rattus norvegicus	102-116
8242236-2	1993	The involvement of calcitonin gene-related peptide (CGRP) in the mechanism of nicotinic acetylcholine receptor-operated noncontractile Ca2+ mobilization (not accompanied by twitch tension) was investigated by measuring Ca(2+)-aequorin luminescence at the neuromuscular junction of mouse diaphragm muscle treated with neostigmine.	Neostigmine	317-328	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	52-56
8362843-6	1993	Neostigmine (10 micrograms/kg im) also increased serum gastrin up to 6100 pg/ml but propranolol (40 micrograms/kg i.v.)	Neostigmine	0-11	gastrin	Homo sapiens	55-62
8499198-3	1993	In the mouse diaphragm nerve-muscle preparations, neostigmine 1 mumol litre-1 continued to produce some antagonism of tubocurarine-induced block after cholinesterase had been inactivated completely by diisopropyl fluorophosphate 22 mumol litre-1.	Neostigmine	50-61	butyrylcholinesterase	Mus musculus	151-165
8499198-7	1993	Although inhibition of acetyl-cholinesterase is the main mechanism of action of neostigmine, the drug also exerts an additional direct action on motor nerve endings to block the delayed rectifier K+ channels and enhance transmitter release.	Neostigmine	80-91	butyrylcholinesterase	Mus musculus	30-44
7683557-2	1993	Pretreatments with neostigmine and cysteamine blunted the GAL-induced GH secretion.	Neostigmine	19-30	galanin and GMAP prepropeptide	Rattus norvegicus	58-61
7683557-2	1993	Pretreatments with neostigmine and cysteamine blunted the GAL-induced GH secretion.	Neostigmine	19-30	gonadotropin releasing hormone receptor	Rattus norvegicus	70-72
8093722-3	1993	The relative anti-AChE potency was in the following order: neostigmine > nizatidine > cimetidine >> famotidine.	Neostigmine	59-70	acetylcholinesterase	Rattus norvegicus	18-22
1332901-1	1992	I. v. administration of carbachol or neostigmine produced a dose-dependent decrease in the angiotensin I pressor response and in conversion of angiotensin I to angiotensin II in anesthetized rats.	Neostigmine	37-48	angiotensinogen	Rattus norvegicus	160-174
1612784-1	1992	The effects of chemical sympathectomy induced by 6-hydroxydopamine (6-OHDA) and administration of the acetylcholinesterase inhibitor neostigmine, singly or together, on gastric carcinogenesis induced by N-methyl-N"-nitro-N-nitrosoguanidine (MNNG), and on the tissue catecholamine concentration of the gastric wall and the labeling index of the gastric mucosa, were investigated in inbred Wistar rats.	Neostigmine	133-144	acetylcholinesterase	Rattus norvegicus	102-122
1421312-1	1992	The mechanism of shortening MEPC decay phase after initial prolongation due to acetylcholinesterase inhibition by armine and neostigmine was studied by use of two-electrode voltage-clamp at the mice diaphragm Factors which switch off non-quantal secretion of acetylcholine from the nerve (acute denervation in vitro, ouabain, high concentration of magnesium ions) only slightly reduced the prolongation of MEPC caused by AChE inhibition.	Neostigmine	125-136	acetylcholinesterase	Mus musculus	79-99
1421312-1	1992	The mechanism of shortening MEPC decay phase after initial prolongation due to acetylcholinesterase inhibition by armine and neostigmine was studied by use of two-electrode voltage-clamp at the mice diaphragm Factors which switch off non-quantal secretion of acetylcholine from the nerve (acute denervation in vitro, ouabain, high concentration of magnesium ions) only slightly reduced the prolongation of MEPC caused by AChE inhibition.	Neostigmine	125-136	acetylcholinesterase	Mus musculus	421-425
1547059-0	1992	Effects of neostigmine and edrophonium on human erythrocyte acetylcholinesterase activity.	Neostigmine	11-22	acetylcholinesterase (Cartwright blood group)	Homo sapiens	60-80
1522952-2	1992	Injections of the cholinesterase inhibitor, neostigmine bromide, induced a stiff, tremulous state and lowered myoclonic, clonic and tonic seizure thresholds.	Neostigmine	44-63	butyrylcholinesterase	Homo sapiens	18-32
1642938-3	1992	Ten patients in each group were given neostigmine 35 micrograms kg-1 when the infusion was stopped when T1/T0 had recovered to 20%; in the others recovery was spontaneous.	Neostigmine	38-49	interleukin 1 receptor like 1	Homo sapiens	104-109
1642938-6	1992	Neostigmine hastened recovery of both T1/T0 and T4/T1 in both groups.	Neostigmine	0-11	interleukin 1 receptor like 1	Homo sapiens	38-43
1642938-6	1992	Neostigmine hastened recovery of both T1/T0 and T4/T1 in both groups.	Neostigmine	0-11	interleukin 1 receptor like 1	Homo sapiens	48-53
1572308-1	1992	We previously reported that the injection of neostigmine, an inhibitor of acetylcholinesterase, into the third cerebral ventricle of fasted rats produced hyperglycemia associated with the secretion of epinephrine and norepinephrine.	Neostigmine	45-56	acetylcholinesterase	Rattus norvegicus	74-94
1547059-2	1992	Erythrocyte AChE activities decreased to 11.3 (SD 1.2)% and 11.4 (0.8)% of baseline values (P less than 0.001) within 2 min, then recovered slowly and were 43.2 (6.2)% and 27.9 (2.9)% (P less than 0.001) 60 min after administration of neostigmine 0.036 mg kg-1 and 0.071 mg kg-1, respectively.	Neostigmine	235-246	acetylcholinesterase (Cartwright blood group)	Homo sapiens	12-16
1513401-3	1992	The AChE inhibition by armine or neostigmine made this difference 10-100 times higher.	Neostigmine	33-44	acetylcholinesterase	Rattus norvegicus	4-8
1630594-3	1992	Application of the cholinesterase inhibitor, neostigmine, directly to the surface of the spinal cord elicited increases in heart rate selectively when neostigmine was applied to upper thoracic segments (Th1-Th4), whereas all thoracic segments participated in the generation of the associated hypertensive response.	Neostigmine	45-56	butyrylcholinesterase	Rattus norvegicus	19-33
1630594-3	1992	Application of the cholinesterase inhibitor, neostigmine, directly to the surface of the spinal cord elicited increases in heart rate selectively when neostigmine was applied to upper thoracic segments (Th1-Th4), whereas all thoracic segments participated in the generation of the associated hypertensive response.	Neostigmine	151-162	butyrylcholinesterase	Rattus norvegicus	19-33
1354401-5	1992	The serum pseudocholinesterase activity was decreased after the injection of atracurium or neostigmine in contrast to vecuronium.	Neostigmine	91-102	butyrylcholinesterase	Felis catus	10-30
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	49-60	butyrylcholinesterase	Rattus norvegicus	17-31
1570386-2	1992	The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg.	Neostigmine	62-73	acetylcholinesterase	Mus musculus	24-44
1570386-2	1992	The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg.	Neostigmine	62-73	acetylcholinesterase	Mus musculus	46-50
1570386-2	1992	The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg.	Neostigmine	75-78	acetylcholinesterase	Mus musculus	24-44
1570386-2	1992	The peripherally acting acetylcholinesterase (AChE) inhibitor neostigmine (NEO) was also found to reliably, though less strongly, antagonize the SCOP induced amnesia at a dose of 0.03 mg/kg.	Neostigmine	75-78	acetylcholinesterase	Mus musculus	46-50
1832920-11	1991	Neostigmine 0.04 mg kg-1 or edrophonium 0.75 mg kg-1 evoked recovery from T1/Tc 9% (SEM 1.2% and 1.0%, respectively) to T4:T1 = 0.7 in 11 (0.6) and 8 (0.9) min (both P less than 0.001 vs spontaneous recovery).	Neostigmine	0-11	CD5 molecule	Homo sapiens	74-82
1933434-2	1991	Intrathecal (IT) injection of the cholinesterase inhibitor, neostigmine (NEO), produced marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	60-71	butyrylcholinesterase	Rattus norvegicus	34-48
1933434-2	1991	Intrathecal (IT) injection of the cholinesterase inhibitor, neostigmine (NEO), produced marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	73-76	butyrylcholinesterase	Rattus norvegicus	34-48
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	49-60	butyrylcholinesterase	Rattus norvegicus	33-36
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	49-60	butyrylcholinesterase	Rattus norvegicus	147-150
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	62-65	butyrylcholinesterase	Rattus norvegicus	17-31
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	62-65	butyrylcholinesterase	Rattus norvegicus	33-36
1940017-5	1991	injection of the cholinesterase (ChE) inhibitor, neostigmine (NEO), produced a significant reduction in spinal, but not medullary tissue levels of ChE, and evoked marked pressor and tachycardic responses without any changes in respiratory parameters.	Neostigmine	62-65	butyrylcholinesterase	Rattus norvegicus	147-150
1940017-8	1991	injection of NEO which inhibited both spinal and medullary ChE, produced characteristic respiratory changes--increased tidal volume and decreased respiratory rate and minute volume, as well as pressor and tachycardic responses.	Neostigmine	13-16	butyrylcholinesterase	Rattus norvegicus	59-62
2215927-4	1990	However, in order to obtain stable and more readily detectable levels, the acetylcholinesterase inhibitor neostigmine was added to the perfusion medium at a concentration of 5 or 10 microM and was used during all subsequent manipulations.	Neostigmine	106-117	acetylcholinesterase	Rattus norvegicus	75-95
1991816-6	1991	In conclusion, cholinergic agonists such as neostigmine are able to increase both basal and GHRH-induced GH secretion in short children even when given intranasally.	Neostigmine	44-55	growth hormone releasing hormone	Homo sapiens	92-96
1991816-6	1991	In conclusion, cholinergic agonists such as neostigmine are able to increase both basal and GHRH-induced GH secretion in short children even when given intranasally.	Neostigmine	44-55	growth hormone 1	Homo sapiens	92-94
2390670-10	1990	Cholinesterase inhibition with neostigmine potentiated the prejunctional effect induced by a low (20 microM) but not a high (50 microM) concentration of Phen.	Neostigmine	31-42	butyrylcholinesterase	Rattus norvegicus	0-14
1973195-3	1990	The presence of neostigmine to inhibit acetylcholinesterase did not alter the relative sensitivities of the tissues to acetylcholine.	Neostigmine	16-27	acetylcholinesterase	Canis lupus familiaris	39-59
2163905-3	1990	Application of the cholinesterase inhibitor (proserine) to the cerebral cortex increased both the amplitude and the duration of the dendritic potential.	Neostigmine	45-54	butyrylcholinesterase	Felis catus	19-33
2284027-4	1990	The reduction of tau accelerated with the temperature rise and occurred after AChE inhibition by neostigmine.	Neostigmine	97-108	acetylcholinesterase	Mus musculus	78-82
1991816-0	1991	Intranasal administration of neostigmine potentiates both intravenous and intranasal growth hormone (GH)-releasing hormone-induced GH release in short children.	Neostigmine	29-40	growth hormone 1	Homo sapiens	85-99
1991816-0	1991	Intranasal administration of neostigmine potentiates both intravenous and intranasal growth hormone (GH)-releasing hormone-induced GH release in short children.	Neostigmine	29-40	growth hormone 1	Homo sapiens	101-103
1991816-0	1991	Intranasal administration of neostigmine potentiates both intravenous and intranasal growth hormone (GH)-releasing hormone-induced GH release in short children.	Neostigmine	29-40	growth hormone 1	Homo sapiens	131-133
1991816-2	1991	The aim of our study was to verify in two groups of children with idiopathic short stature the effect of intranasal administration of neostigmine (inNS; 3 mg), a cholinesterase inhibitor, on basal GH levels as well as on the somatotroph response to GHRH when the peptide was administered either iv (ivGHRH; 1 microgram/kg) or intranasally (inGHRH; 10 micrograms/kg).	Neostigmine	134-145	butyrylcholinesterase	Homo sapiens	162-176
1991816-2	1991	The aim of our study was to verify in two groups of children with idiopathic short stature the effect of intranasal administration of neostigmine (inNS; 3 mg), a cholinesterase inhibitor, on basal GH levels as well as on the somatotroph response to GHRH when the peptide was administered either iv (ivGHRH; 1 microgram/kg) or intranasally (inGHRH; 10 micrograms/kg).	Neostigmine	134-145	growth hormone 1	Homo sapiens	197-199
1991816-2	1991	The aim of our study was to verify in two groups of children with idiopathic short stature the effect of intranasal administration of neostigmine (inNS; 3 mg), a cholinesterase inhibitor, on basal GH levels as well as on the somatotroph response to GHRH when the peptide was administered either iv (ivGHRH; 1 microgram/kg) or intranasally (inGHRH; 10 micrograms/kg).	Neostigmine	134-145	growth hormone releasing hormone	Homo sapiens	249-253
2011475-1	1991	Acetylcholinesterase inhibition with neostigmine in the isolated rat phrenic nerve-hemidiaphragm preparation induced axonal backfiring and repetitive compound muscle action potentials following single nerve stimulation.	Neostigmine	37-48	acetylcholinesterase	Rattus norvegicus	0-20
2073579-8	1990	The augmentation by oxotremorine of evoked acetylcholine release persisted in preparations pretreated with neostigmine (1 microM) and tetrodotoxin (20 nM), which inhibited acetylcholinesterase and oxotremorine-induced spontaneous neural discharges.	Neostigmine	107-118	acetylcholinesterase	Mus musculus	172-192
2118000-6	1990	5) ACh content in the spinal ganglia increased obviously when the degradation of peripheral ACh was inhibited by prostigmine.	Neostigmine	113-124	acyl-CoA thioesterase 12	Rattus norvegicus	3-6
2118000-6	1990	5) ACh content in the spinal ganglia increased obviously when the degradation of peripheral ACh was inhibited by prostigmine.	Neostigmine	113-124	acyl-CoA thioesterase 12	Rattus norvegicus	92-95
2125863-1	1990	In order to investigate the correlation between the peripheral ACh and the primary input of acupuncture sensation, in the paper the cholinesterase inhibitor--Neostigmine and the ACh synthesis blocker--Hemicholine, which are unable to pass through blood brain barrier, and ACh were used as tools to increase or decrease the level of ACh in peripheral nerve system of rats.	Neostigmine	156-169	acyl-CoA thioesterase 12	Rattus norvegicus	63-66
2125863-1	1990	In order to investigate the correlation between the peripheral ACh and the primary input of acupuncture sensation, in the paper the cholinesterase inhibitor--Neostigmine and the ACh synthesis blocker--Hemicholine, which are unable to pass through blood brain barrier, and ACh were used as tools to increase or decrease the level of ACh in peripheral nerve system of rats.	Neostigmine	156-169	butyrylcholinesterase	Rattus norvegicus	132-146
2574406-7	1989	PEP-CK was not changed in fed rats, but increased at 60 and 120 minutes after neostigmine injection into the third cerebral ventricle in fasted rats.	Neostigmine	78-89	phosphoenolpyruvate carboxykinase 1	Rattus norvegicus	0-6
34927331-4	2022	Acetylcholinesterase inhibitors, such as neostigmine and pyridostigmine, delay the degradation of acetylcholine at the synaptic cleft.	Neostigmine	41-52	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
34994010-4	2022	Compound 2d showed the most potent inhibitory activity among the tested molecules toward AChE and BChE (IC50  = 15.07 and 14.15 nM) compared to the standard drug neostigmine.	Neostigmine	162-173	acetylcholinesterase (Cartwright blood group)	Homo sapiens	89-93
34994010-4	2022	Compound 2d showed the most potent inhibitory activity among the tested molecules toward AChE and BChE (IC50  = 15.07 and 14.15 nM) compared to the standard drug neostigmine.	Neostigmine	162-173	butyrylcholinesterase	Homo sapiens	98-102
34435439-3	2022	The aims of the present study were to find suitable doses of sugammadex and neostigmine to reverse a residual vecuronium-induced neuromuscular block from a TOF ratio of 0.3 to 0.9 and evaluate their safety and efficacy.	Neostigmine	76-87	FEZ family zinc finger 2	Homo sapiens	156-159
34540646-7	2021	Neostigmine is a cholinesterase inhibitor that exerts its effect by competitively binding at the active site of acetylcholinesterase, which prevents the hydrolysis of acetylcholine and subsequently retaining acetylcholine at the nerve terminal.	Neostigmine	0-11	butyrylcholinesterase	Homo sapiens	17-31
2607245-4	1989	These effects were inhibited by muscarinic blockade with atropine and enhanced by neostigmine inactivation of acetylcholinesterase.	Neostigmine	82-93	acetylcholinesterase	Rattus norvegicus	110-130
2619740-2	1989	The inhibition kinetics of O-pinacolyl-methylphosphonofluoridate and two carbamates (pyridostigmine and syntostigmine) on the acetylcholinesterase from rat erythrocytes, brain and diaphragm have been studied in vitro.	Neostigmine	104-117	acetylcholinesterase	Rattus norvegicus	126-146
2637954-0	1989	Effect of suxamethonium, pancuronium, neostigmine and halothane on serum cholinesterase activity.	Neostigmine	38-49	butyrylcholinesterase	Homo sapiens	73-87
2576086-6	1989	In in vitro study, weak but significant anti-cholinesterase activity was found in domperidone, the activity being about 1/1,000 of that of neostigmine.	Neostigmine	139-150	butyrylcholinesterase	Canis lupus familiaris	45-59
2619740-4	1989	In vitro addition of pyridostigmine and/or syntostigmine to acetylcholinesterase prior to the organophosphate provided a weak protection against acetylcholinesterase inhibition by this potent organo-phosphorous inhibitor.	Neostigmine	43-56	acetylcholinesterase	Rattus norvegicus	145-165
2619740-4	1989	In vitro addition of pyridostigmine and/or syntostigmine to acetylcholinesterase prior to the organophosphate provided a weak protection against acetylcholinesterase inhibition by this potent organo-phosphorous inhibitor.	Neostigmine	43-56	acetylcholinesterase	Rattus norvegicus	60-80
2552204-10	1989	The addition of prostigmine caused: a) blockade of AChE activity, and b) prostigmine concentration-dependent decrease of Fmax and/or disappearance of m.e.p.p.s from neuromuscular junctions treated with Li+.	Neostigmine	16-27	acetylcholinesterase	Rattus norvegicus	51-55
2462019-4	1989	Neostigmine, an acetylcholinesterase inhibitor, inhibited the K+-induced release of [3H]histamine from cortical slices, and the effect was largely reversed by pirenzepine, an observation suggesting a modulation by endogenous acetylcholine.	Neostigmine	0-11	acetylcholinesterase	Rattus norvegicus	16-36
3204520-3	1988	Likewise, the acetylcholinesterase inhibitor, neostigmine, i.c.v., differentially enhanced hypnotic sensitivity to ethanol in these mouse lines.	Neostigmine	46-57	acetylcholinesterase	Mus musculus	14-34
3251717-4	1988	Neostigmine or eserine, acetylcholinesterase (AchE) inhibitors, produced a larger contraction of the muscle than did Ach.	Neostigmine	0-11	acetylcholinesterase	Bos taurus	24-44
3251717-4	1988	Neostigmine or eserine, acetylcholinesterase (AchE) inhibitors, produced a larger contraction of the muscle than did Ach.	Neostigmine	0-11	acetylcholinesterase	Bos taurus	46-50
20504464-6	1989	Gallamine increased the rate of carbamylation of acetylcholinesterase by physostigmine and neostigmine at low ionic strength; however the data were not consistent with a simple model of complexing inhibition by these carbamates.	Neostigmine	91-102	ACE-1	Oryctolagus cuniculus	49-69
2459657-8	1988	The cholinesterase inhibitor neostigmine increased the amplitude and prolonged the time course of Schwann-cell mepc to a similar degree after short and long term denervation, which indicates that cholinesterase was still functional after 3-4 months of denervation.	Neostigmine	29-40	butyrylcholinesterase	Homo sapiens	4-18
3225383-2	1988	The magnitude of the pressor response to the cholinesterase inhibitor, neostigmine, was greatest when the site of injection was restricted to the thoracic level.	Neostigmine	71-82	butyrylcholinesterase	Rattus norvegicus	45-59
3225383-4	1988	injection of neostigmine (1-10 micrograms) elicited a dose-related increase in mean arterial pressure of up to 45 mm Hg which remained elevated for almost 2 h. Significant inhibition of acetylcholinesterase was localized to the spinal cord, with the thoracic region exhibiting the greatest degree of inhibition.	Neostigmine	13-24	acetylcholinesterase	Rattus norvegicus	186-206
2907002-7	1988	This acetylcholinesterase activity was inhibited by nizatidine (from 10(-5) to 10(-4) M) and this inhibition was similar to that of neostigmine (from 10(-8) to 10(-7) M).	Neostigmine	132-143	acetylcholinesterase	Cavia porcellus	5-25
3179722-3	1988	Picomole amounts of ACh could be measured in the presence of an acetylcholinesterase inhibitor (neostigmine) in the microdialysis perfusion medium (striatal ACh = 0.2-0.4 microM; cortical ACh = 0.03-0.04 microM).	Neostigmine	96-107	acetylcholinesterase	Rattus norvegicus	64-84
2459657-8	1988	The cholinesterase inhibitor neostigmine increased the amplitude and prolonged the time course of Schwann-cell mepc to a similar degree after short and long term denervation, which indicates that cholinesterase was still functional after 3-4 months of denervation.	Neostigmine	29-40	butyrylcholinesterase	Homo sapiens	196-210
3394943-2	1988	Acetylcholinesterase was carbamylated with neostigmine and diluted extensively into buffer to allow decarbamylation to occur.	Neostigmine	43-54	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
3323058-3	1987	Monocrotophos, acothione (organophosphorus compound) and prostigmine are known inhibitors of acetylcholinesterase (AChE).	Neostigmine	57-68	acetylcholinesterase (Cartwright blood group)	Homo sapiens	93-113
3421780-1	1988	The interaction between 2,4 diaminopyridine (2,4-DAP) and neostigmine or edrophonium was studied in vivo in the rat sciatic nerve-tibialis anterior muscle preparation using the constant infusion technique of pancuronium.	Neostigmine	58-69	death-associated protein	Rattus norvegicus	49-52
3421780-3	1988	The ED50 value of 2,4-DAP decreased from 160 to 90 micrograms/kg when 3.5 micrograms/kg neostigmine was added.	Neostigmine	88-99	death-associated protein	Rattus norvegicus	22-25
3421780-4	1988	From these experiments we conclude that 2,4 DAP acts synergistically with both neostigmine and edrophonium.	Neostigmine	79-90	death-associated protein	Rattus norvegicus	44-47
3421780-8	1988	The doses of neostigmine and edrophonium could be halved, when they were combined with a small amount of 2,4-DAP without apparent lose of antagonistic potency.	Neostigmine	13-24	death-associated protein	Rattus norvegicus	109-112
3617097-1	1987	Physostigmine (1.5 mg/kg, s.c.) and neostigmine (1.0 mg/kg, s.c.) injection into male mice produced signs of toxicosis characteristic of cholinesterase inhibition and evoked death in 95 and 94% of the animals respectively.	Neostigmine	36-47	butyrylcholinesterase	Mus musculus	137-151
2443476-3	1987	SP-induced contraction is blocked completely by atropine and augmented by neostigmine.	Neostigmine	74-85	tachykinin precursor 1	Homo sapiens	0-2
3323058-3	1987	Monocrotophos, acothione (organophosphorus compound) and prostigmine are known inhibitors of acetylcholinesterase (AChE).	Neostigmine	57-68	acetylcholinesterase (Cartwright blood group)	Homo sapiens	115-119
2876643-6	1986	Injection of neostigmine (5 X 10(-8) mol), an inhibitor of cholinesterase, into the ventricle resulted in the increase of not only glucose, but also glucagon, epinephrine, and norepinephrine in the hepatic venous plasma.	Neostigmine	13-24	butyrylcholinesterase	Rattus norvegicus	59-73
3573429-4	1987	The visible ChE activity was abolished by pretreatment with neostigmine.	Neostigmine	60-71	butyrylcholinesterase	Canis lupus familiaris	12-15
3559565-3	1987	The presence of an acetylcholinesterase inhibitor (neostigmine) in the perfusion fluid was required for the detection of acetylcholine in the perfusate.	Neostigmine	51-62	acetylcholinesterase	Rattus norvegicus	19-39
3014126-8	1986	Our results support the hypothesis that the effects of neostigmine on the motoneurone terminal are mediated by the prolonged action of acetylcholine that occurs with inhibition of acetylcholinesterase.	Neostigmine	55-66	acetylcholinesterase	Mus musculus	180-200
3524957-1	1986	This review deals mainly with the pharmacokinetics of the reversible quaternary cholinesterase inhibitors neostigmine, pyridostigmine and edrophonium, which are mainly used to antagonise non-depolarising neuromuscular blockade in general anaesthesia and in the symptomatic treatment of myasthenia gravis.	Neostigmine	106-117	butyrylcholinesterase	Homo sapiens	80-94
3774587-3	1986	The perfusion pressure-lowering effect on NT was potentiated and inhibited by neostigmine and atropine, respectively.	Neostigmine	78-89	neurotensin/neuromedin N	Cavia porcellus	42-44
4080605-3	1985	The incidence and amplitude of bradycardia caused by NT were increased by neostigmine but reduced by atropine.	Neostigmine	74-85	neurotensin/neuromedin N	Cavia porcellus	53-55
4078257-2	1985	Neostigmine administration was associated with a marked rise in fetal growth hormone concentrations.	Neostigmine	0-11	somatotropin	Ovis aries	70-84
4078257-3	1985	The integrated release of growth hormone in the hour following fetal neostigmine administration was 2880 +/- 425 ng.min/ml compared to -618 +/- 206 ng .	Neostigmine	69-80	somatotropin	Ovis aries	26-40
4078257-6	1985	In the infant lamb, neostigmine was associated with a lesser (P less than 0.001) but significant (P less than 0.02) growth hormone response.	Neostigmine	20-31	growth hormone 1	Homo sapiens	116-130
4045465-4	1985	The activity was decreased by hemicholinium-3, an inhibitor of choline uptake and slightly activated by neostigmine, an acetylcholinesterase inhibitor.	Neostigmine	104-115	acetylcholinesterase (Cartwright blood group)	Homo sapiens	120-140
4080605-4	1985	Neostigmine and atropine also tended to decrease and increase respectively, the tachycardia caused by NT.	Neostigmine	0-11	neurotensin/neuromedin N	Cavia porcellus	102-104
3999598-7	1985	Local application of cholinesterase inhibitors in the form of Eserine, Prostigmin etc.	Neostigmine	71-81	butyrylcholinesterase	Homo sapiens	21-35
2991804-1	1985	Inhibition of acetylcholinesterase (AChE) by more than 80% by neostigmine or physostigmine resulted in a failure of tetanic contraction (100 Hz) in the isolated mouse nerve-diaphragm preparation.	Neostigmine	62-73	acetylcholinesterase	Mus musculus	14-34
2991804-1	1985	Inhibition of acetylcholinesterase (AChE) by more than 80% by neostigmine or physostigmine resulted in a failure of tetanic contraction (100 Hz) in the isolated mouse nerve-diaphragm preparation.	Neostigmine	62-73	acetylcholinesterase	Mus musculus	36-40
2857786-5	1985	Ambenonium was a less potent antagonist of tissue responses to acetylcholine, and the underestimation in the pKB (as compared to that obtained with bethanechol) could be eliminated by prior treatment of tissues with the acetylcholinesterase inhibitor neostigmine.	Neostigmine	251-262	acetylcholinesterase	Rattus norvegicus	220-240
4026049-6	1985	Subsequently, aminophylline (20 mg/kg) restored Pdi to the control value at every frequency of stimulation (p less than 0.05), whereas neostigmine (0.25 and 1.0 mg) restored Pdi at low frequencies only (p less than 0.05).	Neostigmine	135-146	peptidyl arginine deiminase 1	Homo sapiens	174-177
4010469-5	1985	injection of either soman (10-40 micrograms/kg), neostigmine (75 micrograms/kg) or DFP (350 micrograms/kg) caused marked suppression of behavior and AChE activity of the gut, without affecting brain AChE.	Neostigmine	49-60	acetylcholinesterase	Rattus norvegicus	149-153
4018706-3	1985	Neostigmine (12.5 micrograms/kg) produced a significant rise in plasma VIP level, and the plasma VIP response to neostigmine was significantly greater in the IBS group than in the normal group.	Neostigmine	0-11	vasoactive intestinal peptide	Homo sapiens	71-74
4018706-3	1985	Neostigmine (12.5 micrograms/kg) produced a significant rise in plasma VIP level, and the plasma VIP response to neostigmine was significantly greater in the IBS group than in the normal group.	Neostigmine	113-124	vasoactive intestinal peptide	Homo sapiens	97-100
2858527-4	1985	The ED50 for cholinesterase inhibition by neostigmine (1.4 X 10(-5) M) is approximately 15 fold greater than the ED50 for the augmentation of the response to field stimulation (9.5 X 10(-7) M).	Neostigmine	42-53	butyrylcholinesterase	Rattus norvegicus	13-27
2857526-5	1985	The cholinesterase inhibitor neostigmine also decreases K+-stimulated [3H]acetylcholine overflow, whereas the muscarinic antagonist atropine enhances the overflow of [3H]acetylcholine.	Neostigmine	29-40	butyrylcholinesterase	Rattus norvegicus	4-18
2858526-2	1985	Eseroline afforded 50% protection (ED 50) of erythrocyte AChE against inactivation by 1 microM DFP, physostigmine or neostigmine, at concentrations of 4.3, 22 and 23.5 microM, respectively, while for eel AChE protection against 10 and 30 microM DFP, 0.3 and 1 microM physostigmine and 1 microM neostigmine the eseroline ED 50 values were 0.3, 0.4, 0.7, 1.9 and 5.6 microM, respectively.	Neostigmine	117-128	acetylcholinesterase	Mus musculus	57-61
2858526-2	1985	Eseroline afforded 50% protection (ED 50) of erythrocyte AChE against inactivation by 1 microM DFP, physostigmine or neostigmine, at concentrations of 4.3, 22 and 23.5 microM, respectively, while for eel AChE protection against 10 and 30 microM DFP, 0.3 and 1 microM physostigmine and 1 microM neostigmine the eseroline ED 50 values were 0.3, 0.4, 0.7, 1.9 and 5.6 microM, respectively.	Neostigmine	294-305	acetylcholinesterase	Mus musculus	57-61
6400363-10	1984	Neostigmine, a drug which increases the secretion of endogenous VIP, also increases renin secretion, and this increase is not blocked by renal denervation or propranolol.	Neostigmine	0-11	vasoactive intestinal peptide	Homo sapiens	64-67
6400363-10	1984	Neostigmine, a drug which increases the secretion of endogenous VIP, also increases renin secretion, and this increase is not blocked by renal denervation or propranolol.	Neostigmine	0-11	renin	Homo sapiens	84-89
6094402-7	1984	To answer the first question, we increased base-line Rcs (38.4 +/- 11.8%) by administering an acetylcholinesterase inhibitor, neostigmine (aerosol), through the bronchoscope.	Neostigmine	126-137	acetylcholinesterase	Canis lupus familiaris	94-114
6084002-6	1984	On the other hand, TSM contraction to an ED50 dose of SP was 1) augmented by a mean (+/- SE) of 470 (+/- 110%) following pretreatment with the cholinesterase inhibitor, neostigmine (10(-6) M);2) inhibited by a mean (+/- SE) of 35 (+/- 15%) with the cholinergic antagonist, atropine (10(-4) M); and 3) also inhibited by a mean (+/- SE) of 45 (+/- 11%) following inhibition of acetylcholine synthesis with hemicholinium-3 (10(-4) M).	Neostigmine	169-180	cholinesterase	Oryctolagus cuniculus	143-157
11540833-8	1984	Neostigmine increases plasma VIP and plasma renin activity, and the VIP appears to be responsible for the increase in renin secretion, since the increase is not blocked by renal denervation or propranolol.	Neostigmine	0-11	vasoactive intestinal peptide	Rattus norvegicus	29-32
11540833-8	1984	Neostigmine increases plasma VIP and plasma renin activity, and the VIP appears to be responsible for the increase in renin secretion, since the increase is not blocked by renal denervation or propranolol.	Neostigmine	0-11	renin	Rattus norvegicus	44-49
6656781-5	1983	IgE antibodies in the other sera cross-reacted with the muscle relaxants, other quaternary ammonium compounds and some pharmacologically unrelated drugs including promethazine, morphine, neostigmine and pentolineum.	Neostigmine	187-198	immunoglobulin heavy constant epsilon	Homo sapiens	0-3
6733361-1	1984	Doses of 100, 150 and 200 micrograms kg-1 of the cholinesterase inhibitor neostigmine reverse the anaesthetic action of ketamine.	Neostigmine	74-85	butyrylcholinesterase	Rattus norvegicus	49-63
6491973-1	1984	Microinjection of the acetylcholinesterase inhibitor neostigmine into the dorsal pontine tegmentum of intact, freely moving cats produced significant changes in electrographic desynchronized (D) sleep signs and D sleep-like behavior.	Neostigmine	53-64	acetylcholinesterase	Felis catus	22-42
6610744-9	1984	Diethyldimethylpyrophosphonate , neostigmine, eserine, and di-isopropyl fluorophosphonate inhibited ChE activity in this order of potency.	Neostigmine	33-44	butyrylcholinesterase	Homo sapiens	100-103
6610744-11	1984	Neostigmine, 0.15 and 0.4 microM, increased the time constant of miniature end-plate currents 1.3- and 1.8-fold, and slowed down ChE activity of muscle homogenates by 1.4 and 2.1 times, respectively, without significantly affecting ACh hydrolysis by intact muscles.	Neostigmine	0-11	butyrylcholinesterase	Homo sapiens	129-132
6286926-8	1982	Neostigmine, a selective peripheral cholinesterase inhibitor, induced respiratory paralysis which was not affected by clonidine pretreatment.	Neostigmine	0-11	butyrylcholinesterase	Mus musculus	36-50
6354300-0	1983	[Trial of cholinesterase reactivators as proserine antagonists].	Neostigmine	41-50	butyrylcholinesterase	Mus musculus	10-24
6887013-2	1983	In the heart, the phospholipase A2 inhibitor mepacrine (10(-4) M) reduced the choline efflux (1.1 nmol g-1 min-1) by 51 +/- 5% (N = 3), whereas several cholinesterase inhibitors (physostigmine, neostigmine and diisopropylfluorophosphate) and muscarinic agonists (acetylcholine, oxotremorine and bethanechol) caused an increase.	Neostigmine	194-205	phospholipase A2 group IB	Rattus norvegicus	18-34
6626182-7	1983	The residual labelling (8%) of band I but not band II (4%) was removed by preincubation of partially purified enzyme preparation with neostigmine (a selective inhibitor of cholinesterase).	Neostigmine	134-145	butyrylcholinesterase	Homo sapiens	172-186
7074413-0	1982	Effects of neostigmine and pyridostigmine on serum cholinesterase activity.	Neostigmine	11-22	butyrylcholinesterase	Homo sapiens	51-65
7126246-6	1982	Potent inhibitors of AChE such as bis(4-allyldimethyl ammoniumphenyl) pentan-3-one dibromide (BW 284C51), neostigmine and eserine also inhibited AAA potently.	Neostigmine	106-117	acetylcholinesterase	Ovis aries	21-25
7045869-5	1982	Acetylcholine at 10 nM and the parasympathomimetic anticholinesterase agent neostigmine at 1 microM markedly stimulated LH-RH release.	Neostigmine	76-87	gonadotropin releasing hormone 1	Rattus norvegicus	120-125
6284424-15	1982	These results suggest that at the frog neuromuscular junction the effects of neostigmine are explained primarily by its inhibition of cholinesterase, whereas physostigmine are explained primarily by its inhibition of cholinesterase, whereas physostigmine has an additional action on nerve terminals of decreasing nerve-stimulated release of acetylcholine.	Neostigmine	77-88	butyrylcholinesterase	Homo sapiens	134-148
7070215-3	1982	Neostigmine (1 microgram) and physostigmine (15 microgram) caused nearly maximal and approximately equal degrees of cholinesterase inhibition in several brain regions.	Neostigmine	0-11	butyrylcholinesterase	Rattus norvegicus	116-130
7070215-4	1982	The recovery of the cardiovascular parameters and of brain cholinesterase activity was significantly faster following physostigmine compared to neostigmine.	Neostigmine	144-155	butyrylcholinesterase	Rattus norvegicus	59-73
7055744-0	1982	Effects of neostigmine and pyridostigmine on serum cholinesterase activity.	Neostigmine	11-22	butyrylcholinesterase	Homo sapiens	51-65
7055744-1	1982	Serum cholinesterase activities were measured from 270 minutes in patients following administration of neostigmine or pyridostigmine for the reversal of pancuronium block in groups of seven patients each.	Neostigmine	103-114	butyrylcholinesterase	Homo sapiens	6-20
7439634-8	1980	Hexamethonium strongly inhibited neostigmine-stimulated release of VIP.	Neostigmine	33-44	vasoactive intestinal peptide	Canis lupus familiaris	67-70
7272149-0	1981	Effect of neostigmine and pyridostigmine on the plasma cholinesterase activity.	Neostigmine	10-21	butyrylcholinesterase	Homo sapiens	55-69
7272149-1	1981	The effect of neostigmine 0.05 mg kg-1 or pyridostigmine 0.25 mg kg-1 on serum cholinesterase activity was investigated in 20 adult patients undergoing elective surgery.	Neostigmine	14-25	butyrylcholinesterase	Homo sapiens	79-93
6757008-14	1982	AAA-2 is possibly associated with true acetylcholinesterase (AChE) in brain based on its inhibition by neostigmine but its identity with AChE needs further elucidation.	Neostigmine	103-114	acetylcholinesterase	Rattus norvegicus	61-65
6275065-7	1981	When the acetylcholinesterase was inhibited with diisopropylfluorophosphate, neostigmine, or collagenase treatment to prolong the duration of the nerve-released ACh in the synaptic cleft, desensitization developed during repetitive stimulation of 1000 impulses at 5-33 impulses/sec and then recovered after the conditioning trains, with a time constant of about 25 sec.4.	Neostigmine	77-88	acetylcholinesterase (Cartwright blood group)	Homo sapiens	9-29
7439634-1	1980	The release of vasoactive intestinal peptide (VIP) from the canine gut and its possible neural origin were studied using two agents, oxytocin and neostigmine, known to increase peripheral levels of VIP.	Neostigmine	146-157	vasoactive intestinal peptide	Canis lupus familiaris	198-201
7439634-2	1980	Oxytocin and neostigmine increased the portal concentrations of VIP by threefold and sevenfold, respectively.	Neostigmine	13-24	vasoactive intestinal peptide	Canis lupus familiaris	64-67
6257899-14	1980	Following inhibition of cholinesterase activity by neostigmine, similar effects on m.e.p.c.s and single channel properties were still observed on changing to 2 mM-Sr2+--Ringer.	Neostigmine	51-62	butyrylcholinesterase	Homo sapiens	24-38
7439634-3	1980	A considerable portal/femoral vein gradient ranging from twofold in the basal state to sevenfold during stimulation with neostigmine indicated that the gut was the main source of circulating VIP.	Neostigmine	121-132	vasoactive intestinal peptide	Canis lupus familiaris	191-194
6255718-1	1980	The effects of two anticholinesterases, galanthamine and neostigmine, on ACTH and, in some cases, cortisol were compared in 16 patients undergoing relaxant anaesthesia and surgery for varicose veins.	Neostigmine	57-68	proopiomelanocortin	Homo sapiens	73-77
477734-2	1979	Neostigmine (0.1 micrometer) increased the effectiveness of neurotensin 4-fold.	Neostigmine	0-11	neurotensin/neuromedin N	Cavia porcellus	60-71
7368161-2	1980	Three different anticholinesteratic agents (eserine, neostigmine, and diisopropylphosphorofluoridate) at final concentrations of 10 muM caused complete inhibition of AChE activity after 30 min incubation at room temperature with either platelet-rich plasma or gel-filtered platelets.	Neostigmine	53-64	acetylcholinesterase (Cartwright blood group)	Homo sapiens	166-170
223706-2	1979	2 After the administration of neostigmine or pyridostigmine, acetylcholinesterase activity recovered only slowly due to the covalent nature of the inhibition.	Neostigmine	30-41	acetylcholinesterase	Rattus norvegicus	61-81
6904065-6	1980	However, a similar synergism of lethality caused by neostigmine methylsulfate (0.3 mg/kg, s.c.) after treatment with lithium, which could be eliminated by methylatropine or glycopyrrolate, indicates that lithium may also produce lethal synergism of a cholinesterase (ChE) inhibitor that does not act centrally.	Neostigmine	52-77	butyrylcholinesterase	Rattus norvegicus	251-265
6904065-6	1980	However, a similar synergism of lethality caused by neostigmine methylsulfate (0.3 mg/kg, s.c.) after treatment with lithium, which could be eliminated by methylatropine or glycopyrrolate, indicates that lithium may also produce lethal synergism of a cholinesterase (ChE) inhibitor that does not act centrally.	Neostigmine	52-77	butyrylcholinesterase	Rattus norvegicus	267-270
477734-3	1979	Atropine (0.1 micrometer) completely inhibited the contracting effect of neurotensin measured in the presence of neostigmine, whereas hexamethonium (0.1 micrometer) was without effect.	Neostigmine	113-124	neurotensin/neuromedin N	Cavia porcellus	73-84
193712-3	1977	Rats, treated with neostigmine, a cholinesterase inhibitor, showed a significant decrease in serum beta-lipoprotein and in the incorporation of H3-lysine into the lipoprotein compared to untreated controls.	Neostigmine	19-30	butyrylcholinesterase	Rattus norvegicus	34-48
30781917-2	1979	Three different anticholinesteratic agents (eserine, neostigmine, and diiso- propylphosphorofluoridate) at final concentrations of 10 muM caused complete inhibition of AChE activity after 30 min incubation at room temperature with either platelet-rich plasma or gel-filtered platelets.	Neostigmine	53-64	acetylcholinesterase (Cartwright blood group)	Homo sapiens	168-172
446625-3	1979	Cholesterol ester synthesis in these cultures was inhibited by neostigmine, a cholinesterase inhibitor.	Neostigmine	63-74	butyrylcholinesterase	Rattus norvegicus	78-92
666373-3	1978	Following stimulation however, increased amounts of peripheral plasma VIP are detected, following calcium, pentagastrin and prostigmine release of VIP.	Neostigmine	124-135	vasoactive intestinal peptide	Homo sapiens	70-73
666373-3	1978	Following stimulation however, increased amounts of peripheral plasma VIP are detected, following calcium, pentagastrin and prostigmine release of VIP.	Neostigmine	124-135	vasoactive intestinal peptide	Homo sapiens	147-150
32568-1	1978	The subsynaptic area of mouse diaphragm fibres was hyperpolarized by 1--2 mV during local curarization of the junctional zone in the presence of the reversible anticholinesteraze prostigmine (6 X 10(-6) M), or after treatment of the muscle with organophosphate cholinesterase inhibitor Soman.	Neostigmine	179-190	butyrylcholinesterase	Mus musculus	261-275
195659-5	1977	Steady exposure to acetylcholine abolished both forms of RA.5 Two competitive inhibitors of cholinesterase, neostigmine and ambenonium, were also shown to evoke RA in nerve and muscle.	Neostigmine	108-119	butyrylcholinesterase	Rattus norvegicus	92-106
421888-0	1979	[Age and the effect of proserine on the contractile response of the rectum and inhibition of its cholinesterase in rats].	Neostigmine	23-32	butyrylcholinesterase	Rattus norvegicus	97-111
421888-1	1979	The motor reaction of the rectum strips in rats of 4 age groups and inhibition of its cholinesterase with proserine were studied.	Neostigmine	106-115	butyrylcholinesterase	Rattus norvegicus	86-100
421888-4	1979	The inhibition of cholinesterase occurs in all the age groups from a minimal tested proserine concentration (1.10(10) M), gaining in strength parallel with increasing concentration.	Neostigmine	84-93	butyrylcholinesterase	Rattus norvegicus	18-32
150548-4	1978	A trial of substitutive treatment was undertaken activating the cholinergic system with a precursor of acetylcholine (dimethyl-amino-ethanol-deanol--Bimanol) with simultaneous inhibition of cholinesterase with prostigmin.	Neostigmine	210-220	butyrylcholinesterase	Homo sapiens	190-204
618734-2	1978	These contractions were selectively and reversibly inhibited by carbamate-type cholinesterase inhibitors, such as neostigmine and eserine, and quaternary ammonium compounds, such as tetraethylammonium and decamethonium.	Neostigmine	114-125	butyrylcholinesterase	Rattus norvegicus	79-93
203742-7	1977	Of great significance in ocular myasthenia is the local application of cholinesterase inhibitors like Eserine, Prostigmin or Phospholine Iodide.	Neostigmine	111-121	butyrylcholinesterase	Homo sapiens	71-85
861116-3	1977	On the other hand, in patients with atypical plasma cholinesterase activity, neostigmine potentiated the depolarizing phase of suxamethonium block, while antagonizing the desensitizing phase.	Neostigmine	77-88	butyrylcholinesterase	Homo sapiens	52-66
975633-4	1976	A combination of reserpine plus a cholinesterase inhibitor significantly increased lethality in adult male Swiss-Webster mice above that caused by either neostigmine, physostigmine, or reserpine alone.	Neostigmine	154-165	butyrylcholinesterase	Mus musculus	34-48
984487-0	1976	Serum cholinesterase activity following pancuronium and antagonism with neostigmine or pyridostigmine.	Neostigmine	72-83	butyrylcholinesterase	Homo sapiens	6-20
1138751-0	1975	Potentiation of suxamethonium blockade by neostigmine in patients with atypical cholinesterase.	Neostigmine	42-53	butyrylcholinesterase	Homo sapiens	80-94
49801-0	1975	Thymopoietin and myasthenia gravis: neostigmine-responsive neuromuscular block produced in mice by a synthetic peptide fragment of thymopoietin.	Neostigmine	36-47	thymopoietin	Mus musculus	0-12
49801-0	1975	Thymopoietin and myasthenia gravis: neostigmine-responsive neuromuscular block produced in mice by a synthetic peptide fragment of thymopoietin.	Neostigmine	36-47	thymopoietin	Mus musculus	131-143
49801-2	1975	A synthetic peptide corresponding to positions 29-41 of bovine thymopoietin II, which can reproduce this function of the parent molecule in vitro, also caused neostigmine-responsive neuromuscular block in mice similar to that which thymopoietin itself produces, and which resembles the neuromuscular block of myasthenia gravis.	Neostigmine	159-170	thymopoietin	Bos taurus	63-78
49801-2	1975	A synthetic peptide corresponding to positions 29-41 of bovine thymopoietin II, which can reproduce this function of the parent molecule in vitro, also caused neostigmine-responsive neuromuscular block in mice similar to that which thymopoietin itself produces, and which resembles the neuromuscular block of myasthenia gravis.	Neostigmine	159-170	thymopoietin	Mus musculus	63-75
765884-12	1975	These data indicate: (1) that from HFs incubated in vitro, Ach is able to release a factor (most probably LH-RH) which increases the secretion of LH from AP tissue; (2) that this effect of Ach follows the general rules of cholinergic systems (blockade by atropine, potentiation by prostigmine, etc.	Neostigmine	281-292	gonadotropin releasing hormone 1	Rattus norvegicus	106-111
4343315-2	1972	Studies involving the electrophoretic administration of antagonists of ACh (atropine, DHbetaE) and cholinesterase inhibitors (neostigmine, physostigmine) to MGN neurones indicate that ACh is an excitatory transmitter in the feline MGN, most probably released from fibres which originate in or traverse the mesencephalon.2.	Neostigmine	126-137	butyrylcholinesterase	Homo sapiens	99-113
13956631-0	1962	[Changes of cardiac activity of myasthenic patients during the use of anti-cholinesterase preparations (oxazil and proserine)].	Neostigmine	115-124	butyrylcholinesterase	Homo sapiens	75-89
5774048-2	1969	Carbon-14 labelled 3-hydroxyphenyltrimethylammonium (3-OH PTMA), an active metabolite of neostigmine, has been given to rats by intramuscular injection and its excretion, distribution and metabolism have been studied.2.	Neostigmine	89-100	prothymosin alpha	Rattus norvegicus	58-62
5774048-11	1969	It is concluded that the duration of action of neostigmine is determined by its rapid renal excretion and by its metabolism to the glucuronide conjugate of 3-OH PTMA.	Neostigmine	47-58	prothymosin alpha	Rattus norvegicus	161-165
5967132-0	1966	[Correlation of changes in the adrenocortical function and cholinesterase activity of the blood and brain under the influence of proserine].	Neostigmine	129-138	butyrylcholinesterase	Homo sapiens	59-73
14331249-0	1965	[PROTECTION EXERCISED BY CHOLINESTERASE INHIBITORS WITH 1 OR 2 QUATERNARY AMMONIUM FUNCTIONS AGAINST THE INHIBITORY CAPACITY OF PROSTIGMINE].	Neostigmine	128-139	butyrylcholinesterase	Homo sapiens	25-39
14099400-0	1963	[ON THE INHIBITION OF THE HISTOCHEMICAL ACETYLCHOLINESTERASE REACTION ON MOTOR END-PLATES BY INJECTIONS OF NEOSTIGMINE AND PHYSOSTIGMINE].	Neostigmine	107-118	acetylcholinesterase (Cartwright blood group)	Homo sapiens	40-60
13939168-0	1962	Hydrolysis of neostigmine by plasma cholinesterase.	Neostigmine	14-25	butyrylcholinesterase	Homo sapiens	36-50
5957441-0	1966	Serum cholinesterase in anaesthesia with reference to neostigmine, fentanyl, and dihydrobenzpiridol.	Neostigmine	54-65	butyrylcholinesterase	Homo sapiens	6-20
13697391-0	1961	Improving insulin therapy with neostigmine.	Neostigmine	31-42	insulin	Homo sapiens	10-17
13823694-0	1960	Reactivation of neostigmine inhibited human plasma cholinesterase.	Neostigmine	16-27	butyrylcholinesterase	Homo sapiens	51-65
13234044-0	1955	Inactivation of cholinesterase by compounds related to neostigmine.	Neostigmine	55-66	butyrylcholinesterase	Homo sapiens	16-30
13781449-0	1960	[Blood cholinesterase during the treatment of myasthenia by anti-cholinesterase drugs (prostigmine and mestinon)].	Neostigmine	87-98	butyrylcholinesterase	Homo sapiens	7-21
13781449-0	1960	[Blood cholinesterase during the treatment of myasthenia by anti-cholinesterase drugs (prostigmine and mestinon)].	Neostigmine	87-98	butyrylcholinesterase	Homo sapiens	65-79
13536279-1	1958	The relative potencies of eserine and neostigmine were determined on three preparations of cholinesterase.	Neostigmine	38-49	butyrylcholinesterase	Equus caballus	91-105
13536279-2	1958	Eserine was found to be twice as potent as neostigmine on the pseudocholinesterase of horse plasma, half as potent on the true cholinesterase of cat central nervous system, but twelve times as potent on the true cholinesterase prepared from the leech body wall.	Neostigmine	43-54	butyrylcholinesterase	Equus caballus	68-82
13536279-5	1958	The longer lasting potentiation after neostigmine on the other hand suggests that this anticholinesterase becomes more firmly attached to the cholinesterase receptors in this muscle than does eserine.	Neostigmine	38-49	butyrylcholinesterase	Equus caballus	91-105
13314695-0	1955	The interaction of tensilon and neostigmine with acetylcholinesterase.	Neostigmine	32-43	acetylcholinesterase (Cartwright blood group)	Homo sapiens	49-69
14934691-0	1951	[Qualitative studies on the inhibition of the cholinesterase in erythrocytes by prostigmine and choline].	Neostigmine	80-91	butyrylcholinesterase	Homo sapiens	46-60
13062582-0	1953	[Atropine interference of prostigmine effect on human blood cholinesterase].	Neostigmine	26-37	butyrylcholinesterase	Homo sapiens	60-75
14953258-0	1952	[Inhibition of cholinesterase by prostigmine].	Neostigmine	33-44	butyrylcholinesterase	Homo sapiens	15-29
14926259-0	1951	[Aneurine and cholinesterase after inhibition by prostigmine].	Neostigmine	49-60	butyrylcholinesterase	Homo sapiens	14-28
33359001-15	2021	Auraptene has a mechanism of action similar to that of the acetylcholinesterase inhibitor, neostigmine.	Neostigmine	91-102	acetylcholinesterase	Mus musculus	59-79
20341382-0	1946	Protection against the toxic effects of a prostigmine analogue by insulin.	Neostigmine	42-53	insulin	Homo sapiens	66-73
33933169-9	2021	RESULTS: Addition of neostigmine to selective or non-selective NSAIDs (celecoxib or diclofenac) causes an increased level of analgesia of NSAIDs with rapid onset of action and short duration, while causing potentiation of the anti-inflammatory effect of neostigmine as seen in the tail clip, writhing, formalin test, Cox-1 and Cox-2 activities, serum beta-endorphin, TNF-alpha, NF-kB and HS-CRP.	Neostigmine	21-32	cytochrome c oxidase I, mitochondrial	Rattus norvegicus	317-322
33933169-9	2021	RESULTS: Addition of neostigmine to selective or non-selective NSAIDs (celecoxib or diclofenac) causes an increased level of analgesia of NSAIDs with rapid onset of action and short duration, while causing potentiation of the anti-inflammatory effect of neostigmine as seen in the tail clip, writhing, formalin test, Cox-1 and Cox-2 activities, serum beta-endorphin, TNF-alpha, NF-kB and HS-CRP.	Neostigmine	21-32	cytochrome c oxidase II, mitochondrial	Rattus norvegicus	327-332
33933169-9	2021	RESULTS: Addition of neostigmine to selective or non-selective NSAIDs (celecoxib or diclofenac) causes an increased level of analgesia of NSAIDs with rapid onset of action and short duration, while causing potentiation of the anti-inflammatory effect of neostigmine as seen in the tail clip, writhing, formalin test, Cox-1 and Cox-2 activities, serum beta-endorphin, TNF-alpha, NF-kB and HS-CRP.	Neostigmine	21-32	tumor necrosis factor	Rattus norvegicus	367-376
33933169-9	2021	RESULTS: Addition of neostigmine to selective or non-selective NSAIDs (celecoxib or diclofenac) causes an increased level of analgesia of NSAIDs with rapid onset of action and short duration, while causing potentiation of the anti-inflammatory effect of neostigmine as seen in the tail clip, writhing, formalin test, Cox-1 and Cox-2 activities, serum beta-endorphin, TNF-alpha, NF-kB and HS-CRP.	Neostigmine	21-32	RELA proto-oncogene, NF-kB subunit	Rattus norvegicus	378-383
33933169-9	2021	RESULTS: Addition of neostigmine to selective or non-selective NSAIDs (celecoxib or diclofenac) causes an increased level of analgesia of NSAIDs with rapid onset of action and short duration, while causing potentiation of the anti-inflammatory effect of neostigmine as seen in the tail clip, writhing, formalin test, Cox-1 and Cox-2 activities, serum beta-endorphin, TNF-alpha, NF-kB and HS-CRP.	Neostigmine	21-32	C-reactive protein	Rattus norvegicus	391-394
33381696-0	2020	Retrospective evaluation of the effects of sugammadex and neostigmine on the IgE and eosinophil cationic protein in morbid obese patients.	Neostigmine	58-69	immunoglobulin heavy constant epsilon	Homo sapiens	77-80
33379009-6	2021	Ki values were 4.27 mumol L-1 for neostigmine (an AChE inhibitor) and 0.40 mmol L-1 for acarbose (an alpha-glu inhibitor).	Neostigmine	34-45	acetylcholinesterase (Cartwright blood group)	Homo sapiens	50-54
33188600-13	2020	CONCLUSIONS: Use of sugammadex in replacement of neostigmine would result in significantly lower rNMB/PP related complications but at a substantially higher medication cost.	Neostigmine	49-60	neuromedin B	Rattus norvegicus	97-101
31396774-4	2020	Pleasingly, synthesized compounds show noteworthy acetylcholinesterase (AChE) inhibitory activity with much lower IC50 values 0.0269 +- 0.0021-1.1725 +- 0.0112 muM than standard Neostigmine methylsulphate.	Neostigmine	178-204	acetylcholinesterase (Cartwright blood group)	Homo sapiens	50-70
31396774-4	2020	Pleasingly, synthesized compounds show noteworthy acetylcholinesterase (AChE) inhibitory activity with much lower IC50 values 0.0269 +- 0.0021-1.1725 +- 0.0112 muM than standard Neostigmine methylsulphate.	Neostigmine	178-204	acetylcholinesterase (Cartwright blood group)	Homo sapiens	72-76
33381696-0	2020	Retrospective evaluation of the effects of sugammadex and neostigmine on the IgE and eosinophil cationic protein in morbid obese patients.	Neostigmine	58-69	ribonuclease A family member 3	Homo sapiens	85-112
32761307-7	2020	Addition of the AChE inhibitors neostigmine and territrem B reduced apoptotic cell death under normal culture conditions.	Neostigmine	32-43	acetylcholinesterase (Cartwright blood group)	Homo sapiens	16-20
30373445-3	2020	Neostigmine is an acetylcholinesterase inhibitor that increases frequency of smooth muscle contraction by increasing acetylcholine at autonomic nervous system synapses.	Neostigmine	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	18-38
32189127-6	2020	Our results revealed for the first time that treatment with neostigmine (an acetylcholinesterase inhibitor that no crosses the BBB) was able to revert ROS production and change anti-oxidant enzyme catalase in the cerebral cortex in asthmatic mice.	Neostigmine	60-71	acetylcholinesterase	Mus musculus	76-96
32416089-3	2020	To restore neuromuscular transmission and skeletal muscle strength, anesthesiologists typically administer peripherally acting acetylcholinesterase inhibitors such as neostigmine.	Neostigmine	167-178	acetylcholinesterase (Cartwright blood group)	Homo sapiens	127-147
32416089-8	2020	Peripherally acting acetylcholinesterase inhibitors such as neostigmine should then only be administered when indicated and dosed based on results of the train-of-four ratio.	Neostigmine	60-71	acetylcholinesterase (Cartwright blood group)	Homo sapiens	20-40
32011735-1	2020	Acetylcholine (ACh) spillover from motor endplates occurs after neuronal firing bursts being potentiated by cholinesterase inhibitors (e.g. neostigmine).	Neostigmine	140-151	butyrylcholinesterase	Rattus norvegicus	108-122
32189127-7	2020	These results support the communication between the peripheral immune system and the CNS and suggest that acetylcholinesterase inhibitors, such as neostigmine, should be further studied as possible therapeutic strategies for neuroprotection in asthma.	Neostigmine	147-158	acetylcholinesterase	Mus musculus	106-126
32317886-2	2020	Even intermediate-acting NMBAs may have a prolonged effect resulting in residual weakness after reversal with acetylcholinesterase inhibitors (neostigmine).	Neostigmine	143-154	acetylcholinesterase (Cartwright blood group)	Homo sapiens	110-130
32304958-12	2020	Residual NMB incidence following neostigmine remained at or above 95% for the first 60 min after administration.	Neostigmine	33-44	neuromedin B	Homo sapiens	9-12
31411109-9	2020	The use of neostigmine as a continuous subcutaneous infusion may have a role in the management of such patients, particularly when enteral administration of acetylcholinesterase inhibitors is no longer possible.	Neostigmine	11-22	acetylcholinesterase (Cartwright blood group)	Homo sapiens	157-177
31650189-7	2019	Reversal by administration of the acetylcholinesterase inhibitor neostigmine reduces the incidence of residual neuromuscular block to 15.4%, in combination with calibrated acceleromyography to 3.3%.	Neostigmine	65-76	acetylcholinesterase (Cartwright blood group)	Homo sapiens	34-54
31626713-5	2020	Bilateral injection into the DH of the acetylcholinesterase inhibitor (Neostigmine) reduced baroreflex responses.	Neostigmine	71-82	acetylcholinesterase	Rattus norvegicus	39-59
31332773-5	2020	We showed that CAP activation by neostigmine reduced the levels of pro-inflammatory cytokines (IL-4, IL-5, IL-13, IL-1beta, and TNF-alpha), which resulted in a decrease of eosinophils influx.	Neostigmine	33-44	interleukin 4	Mus musculus	95-99
31332773-5	2020	We showed that CAP activation by neostigmine reduced the levels of pro-inflammatory cytokines (IL-4, IL-5, IL-13, IL-1beta, and TNF-alpha), which resulted in a decrease of eosinophils influx.	Neostigmine	33-44	interleukin 5	Mus musculus	101-105
31332773-5	2020	We showed that CAP activation by neostigmine reduced the levels of pro-inflammatory cytokines (IL-4, IL-5, IL-13, IL-1beta, and TNF-alpha), which resulted in a decrease of eosinophils influx.	Neostigmine	33-44	interleukin 13	Mus musculus	107-112
31332773-5	2020	We showed that CAP activation by neostigmine reduced the levels of pro-inflammatory cytokines (IL-4, IL-5, IL-13, IL-1beta, and TNF-alpha), which resulted in a decrease of eosinophils influx.	Neostigmine	33-44	interleukin 1 beta	Mus musculus	114-122
31332773-5	2020	We showed that CAP activation by neostigmine reduced the levels of pro-inflammatory cytokines (IL-4, IL-5, IL-13, IL-1beta, and TNF-alpha), which resulted in a decrease of eosinophils influx.	Neostigmine	33-44	tumor necrosis factor	Mus musculus	128-137
31332773-6	2020	Furthermore, neostigmine also conferred airway protection against oxidative stress, attenuating ROS production through the increase of antioxidant defense, evidenced by the catalase (CAT) activity.	Neostigmine	13-24	catalase	Mus musculus	173-181
31332773-6	2020	Furthermore, neostigmine also conferred airway protection against oxidative stress, attenuating ROS production through the increase of antioxidant defense, evidenced by the catalase (CAT) activity.	Neostigmine	13-24	catalase	Mus musculus	183-186
31299187-6	2019	However, exposure of DSM strips from control animals to acetylcholinesterase (AChE) inhibitor, neostigmine (1-10 muM) largely reproduced alterations in EFS contractions observed in diabetic DSM complicated by cystitis.	Neostigmine	95-106	acetylcholinesterase	Rattus norvegicus	56-76
31299187-6	2019	However, exposure of DSM strips from control animals to acetylcholinesterase (AChE) inhibitor, neostigmine (1-10 muM) largely reproduced alterations in EFS contractions observed in diabetic DSM complicated by cystitis.	Neostigmine	95-106	acetylcholinesterase	Rattus norvegicus	78-82
30478812-9	2019	Neostigmine significantly enhanced EFS responses, confirming its selectivity for inhibiting acetylcholinesterase which is responsible for termination of acetylcholine.	Neostigmine	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	92-112
30088792-7	2019	Structural analysis revealed that neostigmine reaches the AChE binding site reported elsewhere, whereas fucosterol can act as a no-competitive and competitive acetylcholinesterase inhibitor, in agree with kinetic enzymatic experiments.	Neostigmine	34-45	acetylcholinesterase (Cartwright blood group)	Homo sapiens	58-62
30088792-8	2019	Binding free energy calculations revealed that fucosterol reaches the acetylcholinesterase binding site with higher affinity than neostigmine, which is according to experimental results.	Neostigmine	130-141	acetylcholinesterase (Cartwright blood group)	Homo sapiens	70-90
30311722-5	2019	We assessed the effect of the RET inhibitor on propulsive motility via quantification of fecal pellet output (FPO) induced by the acetylcholinesterase inhibitor neostigmine.	Neostigmine	161-172	ret proto-oncogene	Rattus norvegicus	30-33
31194017-0	2019	The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: A review of recent clinical applications.	Neostigmine	52-63	acetylcholinesterase (Cartwright blood group)	Homo sapiens	12-32
30804708-7	2019	Treatment with physostigmine or neostigmine significantly reduced ROS production and CD11b upregulation by PMNs 20 h after CLP induction.	Neostigmine	32-43	integrin subunit alpha M	Rattus norvegicus	85-90
29479387-2	2018	Agents that inhibit acetylcholinesterase, such as neostigmine, may precipitate myotonia, and are therefore relatively contraindicated.	Neostigmine	50-61	acetylcholinesterase (Cartwright blood group)	Homo sapiens	20-40
30380560-7	2019	The acetylcholinesterase inhibitor, neostigmine (NEO; 0.5 mumol/L), also decreased transmitter exocytosis.	Neostigmine	36-47	acetylcholinesterase (Cartwright blood group)	Homo sapiens	4-24
30380560-7	2019	The acetylcholinesterase inhibitor, neostigmine (NEO; 0.5 mumol/L), also decreased transmitter exocytosis.	Neostigmine	49-52	acetylcholinesterase (Cartwright blood group)	Homo sapiens	4-24
30223917-4	2018	Here we present a reaction for identification of carbamate-type drugs, based on the precipitation of barium carbonate upon treating the analytes with barium hydroxide solution at 80  C. This method works well for carbamate drugs with noteworthy water solubility like carbachol, neostigmine bromide, and pyridostigmine bromide, and could be considered as a method for second identification of these drugs in pharmacopoeias and in Deutscher Arzneimittel-Codex/Neues Rezeptur-Formularium (DAC-NRF).	Neostigmine	278-297	arylacetamide deacetylase	Homo sapiens	486-489
30223917-4	2018	Here we present a reaction for identification of carbamate-type drugs, based on the precipitation of barium carbonate upon treating the analytes with barium hydroxide solution at 80  C. This method works well for carbamate drugs with noteworthy water solubility like carbachol, neostigmine bromide, and pyridostigmine bromide, and could be considered as a method for second identification of these drugs in pharmacopoeias and in Deutscher Arzneimittel-Codex/Neues Rezeptur-Formularium (DAC-NRF).	Neostigmine	278-297	NFKB repressing factor	Homo sapiens	490-493
30403599-1	2018	Acetylcholinesterase inhibitors, including Neostigmine, have been used to reverse neuromuscular blockage for many years.	Neostigmine	43-54	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
30402044-2	2018	Neostigmine suppressed (p < 0.05) LPS-stimulated synthesis of cytokines such as interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the POA, and this effect was similar to that induced by the treatment with systemic AChE inhibitor-donepezil (2.5 mg/animal).	Neostigmine	0-11	interleukin 6	Homo sapiens	109-113
30402044-2	2018	Neostigmine suppressed (p < 0.05) LPS-stimulated synthesis of cytokines such as interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the POA, and this effect was similar to that induced by the treatment with systemic AChE inhibitor-donepezil (2.5 mg/animal).	Neostigmine	0-11	tumor necrosis factor	Homo sapiens	119-152
30402044-2	2018	Neostigmine suppressed (p < 0.05) LPS-stimulated synthesis of cytokines such as interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the POA, and this effect was similar to that induced by the treatment with systemic AChE inhibitor-donepezil (2.5 mg/animal).	Neostigmine	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	240-244
29092846-5	2018	A role for BDNF-mediated enhancement of prejunctional cholinergic transmission in BO is supported by the significant increase in the atropine- and neostigmine-sensitive component of nerve-evoked contractions and upregulation of choline acetyltransferase, vesicular acetylcholine transporter, and transporter Oct2 and -alpha1 receptors.	Neostigmine	147-158	brain derived neurotrophic factor	Homo sapiens	11-15
29915209-6	2018	Cholinergic responses, induced by electric-field stimulation (EFS), bath application of the cholinergic agonist carbachol, or the acetylcholinesterase inhibitor neostigmine were all significantly smaller in TRPC4-/- detrusor strips than wild-type.	Neostigmine	161-172	acetylcholinesterase	Mus musculus	130-150
29915209-6	2018	Cholinergic responses, induced by electric-field stimulation (EFS), bath application of the cholinergic agonist carbachol, or the acetylcholinesterase inhibitor neostigmine were all significantly smaller in TRPC4-/- detrusor strips than wild-type.	Neostigmine	161-172	transient receptor potential cation channel, subfamily C, member 4	Mus musculus	207-212
29620652-7	2018	LESSONS: Our case suggests that neostigmine, an acetylcholinesterase inhibitor, may warrant further investigation in patients with thyroid storm-induced severe sinus tachycardia.	Neostigmine	32-43	acetylcholinesterase (Cartwright blood group)	Homo sapiens	48-68
29023733-7	2017	Nanoinjections of the muscarinic acetylcholine receptor (mAChR) agonist, oxotremorine, or the cholinesterase inhibitor, neostigmine (NEOS), in the rRPa of anaesthetized rats decreased cold-evoked BAT sympathetic nerve activity (SNA, nadirs: -72 and -95%), BAT temperature (Tbat, -0.5 and -0.6 C), expired CO2 (Exp.	Neostigmine	120-131	butyrylcholinesterase	Rattus norvegicus	94-108
29317084-4	2018	Several reports described that cholinesterase inhibitors drugs, like neostigmine, may produce a dose-dependent life-threatening bradycardia in heart transplant recipients while other publication described the safe use of neostigmine.	Neostigmine	69-80	butyrylcholinesterase	Homo sapiens	31-45
29317084-4	2018	Several reports described that cholinesterase inhibitors drugs, like neostigmine, may produce a dose-dependent life-threatening bradycardia in heart transplant recipients while other publication described the safe use of neostigmine.	Neostigmine	221-232	butyrylcholinesterase	Homo sapiens	31-45
29768876-6	2018	PON1 activity increased (42%-35.2%) and glucose concentrations increased (91.5%-81.5%) by 400 mug/kg neostigmine or neostigmine + atropine.	Neostigmine	101-112	paraoxonase 1	Rattus norvegicus	0-4
29768876-6	2018	PON1 activity increased (42%-35.2%) and glucose concentrations increased (91.5%-81.5%) by 400 mug/kg neostigmine or neostigmine + atropine.	Neostigmine	116-127	paraoxonase 1	Rattus norvegicus	0-4
29768876-7	2018	Brain AChE activity remained unchanged but BChE activity showed 18.3% increment after 400 mug/kg neostigmine.	Neostigmine	97-108	butyrylcholinesterase	Rattus norvegicus	43-47
29768876-8	2018	Rats treated with 400 mug/kg neostigmine or neostigmine + atropine had normal neuronal appearance in cortex and hippocampus and weak GFAP expression in hippocampus.	Neostigmine	29-40	glial fibrillary acidic protein	Rattus norvegicus	133-137
29768876-8	2018	Rats treated with 400 mug/kg neostigmine or neostigmine + atropine had normal neuronal appearance in cortex and hippocampus and weak GFAP expression in hippocampus.	Neostigmine	44-55	glial fibrillary acidic protein	Rattus norvegicus	133-137
28806470-1	2017	BACKGROUND: Acetylcholinesterase inhibitors, such as neostigmine, have traditionally been used for reversal of non-depolarizing neuromuscular blocking agents.	Neostigmine	53-64	acetylcholinesterase (Cartwright blood group)	Homo sapiens	12-32
28749013-13	2017	In the presence of the cholinesterase inhibitor neostigmine, EFS led to an additional increase in phosphorylation of MYPT1 T853, MYPT1 T696, MBS85 and paxillin.	Neostigmine	48-59	butyrylcholinesterase	Mus musculus	23-37
28749013-13	2017	In the presence of the cholinesterase inhibitor neostigmine, EFS led to an additional increase in phosphorylation of MYPT1 T853, MYPT1 T696, MBS85 and paxillin.	Neostigmine	48-59	protein phosphatase 1, regulatory subunit 12A	Mus musculus	117-122
28749013-13	2017	In the presence of the cholinesterase inhibitor neostigmine, EFS led to an additional increase in phosphorylation of MYPT1 T853, MYPT1 T696, MBS85 and paxillin.	Neostigmine	48-59	protein phosphatase 1, regulatory subunit 12A	Mus musculus	129-134
28749013-13	2017	In the presence of the cholinesterase inhibitor neostigmine, EFS led to an additional increase in phosphorylation of MYPT1 T853, MYPT1 T696, MBS85 and paxillin.	Neostigmine	48-59	protein phosphatase 1, regulatory subunit 12C	Mus musculus	141-146
28849127-1	2017	Our previous study demonstrated that sepsis may decrease the activity of acetylcholinesterase (AChE) at the neuromuscular junction (NMJ) of the diaphragm at 24 h, and thus improve the antagonistic action of neostigmine on rocuronium.	Neostigmine	207-218	acetylcholinesterase	Rattus norvegicus	73-93
28849127-1	2017	Our previous study demonstrated that sepsis may decrease the activity of acetylcholinesterase (AChE) at the neuromuscular junction (NMJ) of the diaphragm at 24 h, and thus improve the antagonistic action of neostigmine on rocuronium.	Neostigmine	207-218	acetylcholinesterase	Rattus norvegicus	95-99
27287524-6	2016	RESULTS: Cholinergic stimulation of the detrusor induced by electrical field stimulation or exogenous application of carbachol or neostigmine evoked contractions consisting of a transient plus a tonic response, which was blocked by ML204, an inhibitor of TRPC4 channels.	Neostigmine	130-141	transient receptor potential cation channel, subfamily C, member 4	Mus musculus	255-260
28190243-7	2017	The acetylcholinesterase inhibitor neostigmine significantly increased amplitude of phasic activity only in bladder strips following castration, and this was prevented by testosterone replacement.	Neostigmine	35-46	acetylcholinesterase (Cartwright blood group)	Homo sapiens	4-24
28496430-9	2017	The inhibitor of AChE neostigmine did not change the firing per se but induced nociceptive activity, sensitive to d-tubocurarine, after pretreatment of meninges with the migraine mediator CGRP.	Neostigmine	22-33	acetylcholinesterase	Rattus norvegicus	17-21
28169488-4	2017	Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE"s active sites.	Neostigmine	103-114	acetylcholinesterase (Cartwright blood group)	Homo sapiens	187-191
28169488-4	2017	Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE"s active sites.	Neostigmine	103-114	acetylcholinesterase (Cartwright blood group)	Homo sapiens	242-246
28169488-4	2017	Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE"s active sites.	Neostigmine	208-219	acetylcholinesterase (Cartwright blood group)	Homo sapiens	187-191
28169488-4	2017	Both materials were able to release rhodamine B in the presence of diisopropylfluorophosphate (DFP) or neostigmine in a concentration-dependent manner via the competitive displacement of AChE through DFP and neostigmine coordination with the AChE"s active sites.	Neostigmine	208-219	acetylcholinesterase (Cartwright blood group)	Homo sapiens	242-246
28894751-0	2017	Peripheral Inhibitor of AChE, Neostigmine, Prevents the Inflammatory Dependent Suppression of GnRH/LH Secretion during the Follicular Phase of the Estrous Cycle.	Neostigmine	30-41	acetylcholinesterase (Cartwright blood group)	Homo sapiens	24-28
28894751-0	2017	Peripheral Inhibitor of AChE, Neostigmine, Prevents the Inflammatory Dependent Suppression of GnRH/LH Secretion during the Follicular Phase of the Estrous Cycle.	Neostigmine	30-41	gonadotropin releasing hormone 1	Homo sapiens	94-98
28894751-3	2017	Peripheral treatment with Donepezil and Neostigmine prevented the LPS-induced decrease (P < 0.05) in LHbeta gene expression in the anterior pituitary gland (AP) and in LH release.	Neostigmine	40-51	luteinizing hormone subunit beta	Homo sapiens	104-110
28894751-4	2017	Moreover, Donepezil completely abolished (P < 0.05) the suppressory effect of inflammation on GnRH synthesis in the preoptic area, when pretreatment with Neostigmine reduced (P < 0.05) the decrease in GnRH content in this hypothalamic structure.	Neostigmine	157-168	gonadotropin releasing hormone 1	Homo sapiens	97-101
28894751-4	2017	Moreover, Donepezil completely abolished (P < 0.05) the suppressory effect of inflammation on GnRH synthesis in the preoptic area, when pretreatment with Neostigmine reduced (P < 0.05) the decrease in GnRH content in this hypothalamic structure.	Neostigmine	157-168	gonadotropin releasing hormone 1	Homo sapiens	207-211
28894751-6	2017	Our study shows that inflammatory dependent changes in the GnRH/LH secretion may be eliminated or reduced by AChE inhibitors suppressing inflammatory reaction only at the periphery such as Neostigmine, without the need for interfering in the central nervous system.	Neostigmine	189-200	gonadotropin releasing hormone 1	Homo sapiens	59-63
28894751-6	2017	Our study shows that inflammatory dependent changes in the GnRH/LH secretion may be eliminated or reduced by AChE inhibitors suppressing inflammatory reaction only at the periphery such as Neostigmine, without the need for interfering in the central nervous system.	Neostigmine	189-200	acetylcholinesterase (Cartwright blood group)	Homo sapiens	109-113
27874086-0	2016	Combined administration of anisodamine and neostigmine rescued acute lethal crush syndrome through alpha7nAChR-dependent JAK2-STAT3 signaling.	Neostigmine	43-54	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	99-110
27874086-0	2016	Combined administration of anisodamine and neostigmine rescued acute lethal crush syndrome through alpha7nAChR-dependent JAK2-STAT3 signaling.	Neostigmine	43-54	Janus kinase 2	Rattus norvegicus	121-125
27874086-0	2016	Combined administration of anisodamine and neostigmine rescued acute lethal crush syndrome through alpha7nAChR-dependent JAK2-STAT3 signaling.	Neostigmine	43-54	signal transducer and activator of transcription 3	Rattus norvegicus	126-131
27874086-1	2016	Previously we showed that Ani (anisodamine)/Neo (neostigmine) combination produced anti-shock effect via activating alpha7 nicotinic acetylcholine receptor (alpha7nAChR).	Neostigmine	49-60	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	157-168
27852231-2	2016	METHODS: A discrete event simulation (DES) model was developed to compare ORs using either neostigmine or sugammadex for NMB reversal over one month.	Neostigmine	91-102	neuromedin B	Homo sapiens	121-124
26840188-1	2016	BACKGROUND: Neostigmine, an acetyl cholinesterase inhibitor, stimulates colonic motor activity and may induce vagally mediated cardiovascular effects.	Neostigmine	12-23	butyrylcholinesterase	Homo sapiens	35-49
26772968-6	2016	In vitro, the enzyme activity of human AChE and BChE was inhibited in a concentration-dependent manner until a residual activity of 4-6% for AChE and 20-30% for BChE (IC 50 human AChE: 0.117 +- 0.007 muM physostigmine, 0.062 +- 0.003 muM neostigmine; IC 50 human BChE: 0.373 +- 0.089 muM neostigmine; 0.059 +- 0.012 muM physostigmine).	Neostigmine	238-249	butyrylcholinesterase	Homo sapiens	48-52
26772968-6	2016	In vitro, the enzyme activity of human AChE and BChE was inhibited in a concentration-dependent manner until a residual activity of 4-6% for AChE and 20-30% for BChE (IC 50 human AChE: 0.117 +- 0.007 muM physostigmine, 0.062 +- 0.003 muM neostigmine; IC 50 human BChE: 0.373 +- 0.089 muM neostigmine; 0.059 +- 0.012 muM physostigmine).	Neostigmine	288-299	butyrylcholinesterase	Homo sapiens	48-52
27377327-3	2016	The most active compounds have potent enzyme inhibiting activity with IC50 values in the range of 0.46-2.1muM (for AChE) and 0.59-8.1muM (for BChE), with moderate selectivity for AChE comparable with that of pyridostigmine and neostigmine.	Neostigmine	227-238	acetylcholinesterase	Mus musculus	179-183
26873081-0	2016	Involvement of M1 and CB1 receptors in the anxiogenic-like effects induced by neostigmine injected into the rat prelimbic medial prefrontal cortex.	Neostigmine	78-89	cannabinoid receptor 1	Rattus norvegicus	22-25
26873081-4	2016	Thus, the present work aimed at verifying if intra-PL administration of neostigmine, an acetylcholinesterase inhibitor, would produce changes in anxiety-like behavior and if these effects are mediated by M1 and CB1 receptor activation.	Neostigmine	72-83	acetylcholinesterase	Rattus norvegicus	88-108
26873081-4	2016	Thus, the present work aimed at verifying if intra-PL administration of neostigmine, an acetylcholinesterase inhibitor, would produce changes in anxiety-like behavior and if these effects are mediated by M1 and CB1 receptor activation.	Neostigmine	72-83	cannabinoid receptor 1	Rattus norvegicus	211-214
26799963-1	2016	INTRODUCTION: Acetylcholinesterase inhibitors (neostigmine, edrophonium) and encapsulating agents (sugammadex and calabadion) can be used to reverse residual neuromuscular blockade (NMB).	Neostigmine	47-58	acetylcholinesterase (Cartwright blood group)	Homo sapiens	14-34
26963316-8	2016	In the Neostigmine Group, although beta2microglobulin and microalbumin were similar, a significant increase was found in the postoperative alpha1microglobulin and cystatin C values.	Neostigmine	7-18	beta-2-microglobulin	Homo sapiens	35-53
26963316-8	2016	In the Neostigmine Group, although beta2microglobulin and microalbumin were similar, a significant increase was found in the postoperative alpha1microglobulin and cystatin C values.	Neostigmine	7-18	cystatin C	Homo sapiens	163-173
26963316-10	2016	The only significant difference was cystatin C value variation in the Neostigmine Group compared to the Sugammadex Group.	Neostigmine	70-81	cystatin C	Homo sapiens	36-46
26499847-5	2015	The cholinesterase inhibitor neostigmine mimicked the effects of electroacupuncture on HMGB1 release and myocardial ischemia reperfusion injury.	Neostigmine	29-40	butyrylcholinesterase	Mus musculus	4-18
26499847-5	2015	The cholinesterase inhibitor neostigmine mimicked the effects of electroacupuncture on HMGB1 release and myocardial ischemia reperfusion injury.	Neostigmine	29-40	high mobility group box 1	Mus musculus	87-92
25104560-6	2015	The acetylcholine-esterase inhibitor, neostigmine rescued LTP in CA1 area at early stage of the disease but not after plaques deposition.	Neostigmine	38-49	carbonic anhydrase 1	Mus musculus	65-68
25519498-2	2015	Confirmation that the sensor responds to changes in extracellular choline was achieved using local perfusion of choline which resulted in an increase in current, and the acetylcholinesterase inhibitor neostigmine which produced a decrease.	Neostigmine	201-212	acetylcholinesterase (Cartwright blood group)	Homo sapiens	170-190
25727643-0	2015	A combination of neostigmine and anisodamine protects against ischemic stroke by activating alpha7nAChR.	Neostigmine	17-28	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	92-103
25968237-4	2015	We used zebrafish as a model for acute and chronic developmental exposure to PB and two related carbamate acetylcholinesterase (AChE) inhibitors, neostigmine bromide (NB) and physostigmine (PS).	Neostigmine	146-165	acetylcholinesterase	Danio rerio	128-132
25819434-10	2015	Finally, trophoblast cells treated with Neo increased the expression of two antigen-presenting cells attracting chemokines, MCP-1, MIP-1alpha and RANTES through muscarinic receptors, and it was prevented by atropine.	Neostigmine	40-43	C-C motif chemokine ligand 2	Homo sapiens	124-129
25819434-10	2015	Finally, trophoblast cells treated with Neo increased the expression of two antigen-presenting cells attracting chemokines, MCP-1, MIP-1alpha and RANTES through muscarinic receptors, and it was prevented by atropine.	Neostigmine	40-43	C-C motif chemokine ligand 3	Homo sapiens	131-141
25819434-10	2015	Finally, trophoblast cells treated with Neo increased the expression of two antigen-presenting cells attracting chemokines, MCP-1, MIP-1alpha and RANTES through muscarinic receptors, and it was prevented by atropine.	Neostigmine	40-43	C-C motif chemokine ligand 5	Homo sapiens	146-152
32262377-7	2015	Furthermore, the presence of the acetylcholinesterase inhibitor neostigmine at concentrations as low as 1 fM was demonstrated, which is even below the necessary detection limit for clinical diagnostics.	Neostigmine	64-75	acetylcholinesterase (Cartwright blood group)	Homo sapiens	33-53
25139304-3	2014	This study investigates, whether pharmacologic acetylcholinesterase inhibition with neostigmine diminishes liver damage in acute liver failure via the cholinergic anti-inflammatory pathway.	Neostigmine	84-95	acetylcholinesterase	Mus musculus	47-67
25440827-0	2014	Reactivity of diabetic urinary bladder to the cholinesterase inhibitor neostigmine.	Neostigmine	71-82	butyrylcholinesterase	Rattus norvegicus	46-60
25440827-1	2014	OBJECTIVE: To examine the effects of neostigmine, an acetylcholinesterase inhibitor that has been used to treat impaired bladder emptying on diabetic rat urinary bladder smooth muscle.	Neostigmine	37-48	acetylcholinesterase	Rattus norvegicus	53-73
25139304-9	2014	CONCLUSIONS: Neostigmine is an acetylcholinesterase inhibitor that ameliorates the effects of APAP-induced acute liver failure in the mouse and therefore may provide new treatment options for affected patients.	Neostigmine	13-24	acetylcholinesterase	Mus musculus	31-51
23476830-1	2013	Neostigmine is a parasympathomimetic drug that acts as a reversible acetylcholinesterase inhibitor.	Neostigmine	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	68-88
24212240-8	2014	RESULTS: Prophylactic and delayed therapeutic application of nicotine, physostigmine, or neostigmine significantly attenuated the severity of acute pancreatitis 12 hours after the induction of severe necrotizing pancreatitis compared with untreated controls as evaluated with histological scores, myeloperoxidase, and high-mobility group box 1 levels (P < 0.05).	Neostigmine	89-100	myeloperoxidase	Rattus norvegicus	297-312
24212240-8	2014	RESULTS: Prophylactic and delayed therapeutic application of nicotine, physostigmine, or neostigmine significantly attenuated the severity of acute pancreatitis 12 hours after the induction of severe necrotizing pancreatitis compared with untreated controls as evaluated with histological scores, myeloperoxidase, and high-mobility group box 1 levels (P < 0.05).	Neostigmine	89-100	high mobility group box 1	Rattus norvegicus	318-343
24032987-1	2013	BACKGROUND AND PURPOSE: Cholinesterase inhibitors such as neostigmine are used for acute colonic pseudo-obstruction, but cardio-bronchial side-effects limit use.	Neostigmine	58-69	butyrylcholinesterase	Homo sapiens	24-38
23671623-5	2013	Physostigmine, which can overcome the blood-brain barrier or neostigmine acting only peripheral, served as acetylcholinesterase inhibitors.	Neostigmine	61-72	acetylcholinesterase	Rattus norvegicus	107-127
23671623-11	2013	Physostigmine and neostigmine significantly decreased the protein expression of IL-1 and TNF-alpha.	Neostigmine	18-29	tumor necrosis factor	Rattus norvegicus	89-98
23671623-12	2013	Neuronal degeneration and the activity of acetylcholinesterase were elevated after surgery with LPS-treatment and reduced by physostigmine and neostigmine.	Neostigmine	143-154	acetylcholinesterase	Rattus norvegicus	42-62
23447584-4	2013	In humans, however, pain responses can be modulated by spinal ACh, as evidenced by the increasingly used analgesic procedure (for postoperative and labor patients) consisting of the epidural injection of the acetylcholinesterase inhibitor neostigmine.	Neostigmine	239-250	acetylcholinesterase (Cartwright blood group)	Homo sapiens	208-228
24357101-3	2014	Plasma samples were prepared on ice and neostigmine metilsulfate added as a cholinesterase inhibitor immediately after sample collection.	Neostigmine	40-64	butyrylcholinesterase	Homo sapiens	76-90
25568788-7	2014	Neostigmine effectiveness to resolve ACPO with only one dose was 89.2% versus 14.65% (P < 0.001, NNT = 1 [95% CI 1-2]).	Neostigmine	0-11	cardiotrophin like cytokine factor 1	Homo sapiens	100-107
24643080-5	2014	Interestingly, the non-BBB-penetrating cholinesterase inhibitor neostigmine also prevents or substantially inhibits those cognitive and fMRI changes.	Neostigmine	64-75	butyrylcholinesterase	Rattus norvegicus	39-53
24215347-2	2013	In the absence of a single drug, the administration of an aminosteroid NMBA, such as rocuronium, followed by reversal using an acetylcholinesterase inhibitor, such as neostigmine, is commonly employed.	Neostigmine	167-178	acetylcholinesterase (Cartwright blood group)	Homo sapiens	127-147
24964452-1	2013	Neostigmine is an acetylcholinesterase inhibitor that is increasingly used as a medical treatment in cases of pseudo-obstruction.	Neostigmine	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	18-38
22750421-9	2013	Neostigmine (10 mumol l(-1)), an acetylcholinesterase inhibitor, mimicked the effects of nicotine.	Neostigmine	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	33-53
22699921-10	2012	In animals lacking functional AChE in the CNS (PRiMA(-/-) mice) the EPSCs resembled those observed in neostigmine but the steady inward current was much smaller, suggesting an adaptation to the absence of AChE.	Neostigmine	102-113	proline rich membrane anchor 1	Mus musculus	47-52
23524625-1	2013	OBJECTIVES: We previously demonstrated that the direct microinjection of cholinesterase inhibitor (neostigmine) into the hippocampus in rats activated the hypothalamo-pituitary -adrenal axis and increased the level of norepinephrine in the plasma.	Neostigmine	99-110	butyrylcholinesterase	Rattus norvegicus	73-87
23106973-7	2012	The protective effects of neostigmine were abolished by selective nAChR antagonist vecuronium but not by mAChR antagonist anisodamine.	Neostigmine	26-37	cholinergic receptor nicotinic beta 1 subunit	Rattus norvegicus	66-71
23106973-8	2012	In addition, the effect of neostigmine disappeared in alpha7nAChR KO mice.	Neostigmine	27-38	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	54-65
22699921-9	2012	The pharmacological inactivation of AChE by neostigmine caused the appearance of an ultra-slow (second range) decay component in eEPSCs and also a continuous inward current interpreted as resulting from a continuous ACh presence.	Neostigmine	44-55	acetylcholinesterase	Mus musculus	36-40
22429221-8	2012	Results of an in vivo experiment on anti-AChE activity showed clearly increased acetylcholine-induced gastric motility on intraduodenal administration of acotiamide, just as observed with the AChE inhibitor neostigmine.	Neostigmine	207-218	acetylcholinesterase	Canis lupus familiaris	41-45
22580739-7	2012	The anti-shock effect of combined anisodamine and neostigmine was abolished in alpha7 nAChR knockout mice.	Neostigmine	50-61	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	79-91
22429221-8	2012	Results of an in vivo experiment on anti-AChE activity showed clearly increased acetylcholine-induced gastric motility on intraduodenal administration of acotiamide, just as observed with the AChE inhibitor neostigmine.	Neostigmine	207-218	acetylcholinesterase	Canis lupus familiaris	192-196
23238471-7	2012	Injection of neostigmine enhanced c-Fos expression in spinal cord neurons.	Neostigmine	13-24	FBJ osteosarcoma oncogene	Mus musculus	34-39
22803143-1	2012	Experiments on outbred albino mice have shown that proserine (reversible cholinesterase inhibitor) and nicotine (nicotinic receptor agonist) in a equivalent dose of 0.2 DL(50)injected 2 h before sepsis induction significantly reduced animal mortality from experimental infection due to reduction of blood concentrations of proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	Neostigmine	51-60	butyrylcholinesterase	Mus musculus	73-87
22803143-1	2012	Experiments on outbred albino mice have shown that proserine (reversible cholinesterase inhibitor) and nicotine (nicotinic receptor agonist) in a equivalent dose of 0.2 DL(50)injected 2 h before sepsis induction significantly reduced animal mortality from experimental infection due to reduction of blood concentrations of proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	Neostigmine	51-60	tumor necrosis factor	Mus musculus	349-358
22803143-1	2012	Experiments on outbred albino mice have shown that proserine (reversible cholinesterase inhibitor) and nicotine (nicotinic receptor agonist) in a equivalent dose of 0.2 DL(50)injected 2 h before sepsis induction significantly reduced animal mortality from experimental infection due to reduction of blood concentrations of proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	Neostigmine	51-60	interleukin 1 beta	Mus musculus	360-368
22803143-1	2012	Experiments on outbred albino mice have shown that proserine (reversible cholinesterase inhibitor) and nicotine (nicotinic receptor agonist) in a equivalent dose of 0.2 DL(50)injected 2 h before sepsis induction significantly reduced animal mortality from experimental infection due to reduction of blood concentrations of proinflammatory cytokines TNF-alpha, IL-1beta, and IL-6.	Neostigmine	51-60	interleukin 6	Mus musculus	374-378
22783145-0	2012	Acetylcholine and an acetylcholinesterase inhibitor neostigmine can aggravate tularemia progress in BALB/c mice.	Neostigmine	52-63	acetylcholinesterase	Mus musculus	21-41
22783145-1	2012	The present experiment was aimed at assessing the application of neostigmine, an acetylcholinesterase (AChE) pseudo-irreversible inhibitor with poor penetration through the hematoencephalitic barrier, and the neurotransmitter acetylcholine (ACh).	Neostigmine	65-76	acetylcholinesterase	Mus musculus	81-101
22783145-1	2012	The present experiment was aimed at assessing the application of neostigmine, an acetylcholinesterase (AChE) pseudo-irreversible inhibitor with poor penetration through the hematoencephalitic barrier, and the neurotransmitter acetylcholine (ACh).	Neostigmine	65-76	acetylcholinesterase	Mus musculus	103-107
22037997-7	2012	Often, acetylcholinesterase inhibitors such as pyridostigmine and neostigmine are also employed to help control symptoms.	Neostigmine	66-77	acetylcholinesterase (Cartwright blood group)	Homo sapiens	7-27
21123674-7	2011	Moreover, like itopride and neostigmine, acotiamide inhibited recombinant human and canine stomach-derived acetylcholinesterase (AChE) activity in vitro.	Neostigmine	28-39	acetylcholinesterase	Canis lupus familiaris	129-133
21168544-2	2011	The capability of IMS in the determination of enzyme kinetics and inhibition studies by the analysis of substrate depletion and/or product formation using only a few microliters of solution has been successfully demonstrated on the example of acetylcholine hydrolysis catalyzed by acetylcholinesterase (AChE) and inhibited by neostigmine and galanthamine.	Neostigmine	326-337	acetylcholinesterase (Cartwright blood group)	Homo sapiens	281-301
21352527-1	2011	INTRODUCTION: Neostigmine is a frequently used acetylcholinesterase inhibitor administered to reverse muscular relaxation caused by nondepolarizing neuromuscular relaxants in patients recovering from general anesthesia.	Neostigmine	14-25	acetylcholinesterase (Cartwright blood group)	Homo sapiens	47-67
21168544-2	2011	The capability of IMS in the determination of enzyme kinetics and inhibition studies by the analysis of substrate depletion and/or product formation using only a few microliters of solution has been successfully demonstrated on the example of acetylcholine hydrolysis catalyzed by acetylcholinesterase (AChE) and inhibited by neostigmine and galanthamine.	Neostigmine	326-337	acetylcholinesterase (Cartwright blood group)	Homo sapiens	303-307
20036651-8	2010	In this model neostigmine and VX affected neuromuscular transmission as anticipated from their known actions on AChE.	Neostigmine	14-25	acetylcholinesterase (Cartwright blood group)	Homo sapiens	112-116
20719927-8	2010	Application of the acetylcholinesterase inhibitor neostigmine significantly decreased the amplitude of glutamatergic neurotransmission to CVNs on stimulation of trigeminal fibers.	Neostigmine	50-61	acetylcholinesterase (Cartwright blood group)	Homo sapiens	19-39
21720188-4	2011	Neostigmine, an acetylcholinesterase inhibitor (2, 4, 8 or 16 mug), inhibited the inflammatory pain induced by carrageenan (250 mug/paw), but not the hyperalgesia induced by prostaglandin E2 (2 mug/paw).	Neostigmine	0-11	acetylcholinesterase	Rattus norvegicus	16-36
21034627-8	2010	Acetylcholinesterase antibody occurred more frequently in acetylcholine receptor antibody negative patients with adverse reactions to neostigmine test.	Neostigmine	134-145	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
21120165-2	2010	Neostigmine, an acetylcholinesterase inhibitor, has been used in patients in whom supportive therapy failed to resolve ACPO.	Neostigmine	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	16-36
20133391-6	2010	After a submaximal dose of atropine, potentiation of the remaining parasympathetic effect with the acetylcholinesterase antagonist neostigmine significantly restored postprandial insulin sensitization in a dose-dependent manner with peak effect at 0.1 microg/kg/min.	Neostigmine	131-142	acetylcholinesterase	Rattus norvegicus	99-119
20555429-6	2010	Perindopril (2.71 x 10(-7) mol/L) and neostigmine (1.49 x 10(-7) mol/L) inhibited true cholinesterase and pseudocholinesterase enzyme activity in blood.	Neostigmine	38-49	cholinesterase	Oryctolagus cuniculus	87-101
20555429-6	2010	Perindopril (2.71 x 10(-7) mol/L) and neostigmine (1.49 x 10(-7) mol/L) inhibited true cholinesterase and pseudocholinesterase enzyme activity in blood.	Neostigmine	38-49	cholinesterase	Oryctolagus cuniculus	106-126
20138518-1	2010	Reversible inhibitors (e.g., pyridostigmine bromide, neostigmine bromide) of carbamate origin are used in the early treatment of Myasthenia gravis (MG) to block acetylcholinesterase (AChE) native function and conserve efficient amount of acetylcholine for decreasing number of nicotinic receptors.	Neostigmine	53-72	acetylcholinesterase (Cartwright blood group)	Homo sapiens	161-181
20138518-1	2010	Reversible inhibitors (e.g., pyridostigmine bromide, neostigmine bromide) of carbamate origin are used in the early treatment of Myasthenia gravis (MG) to block acetylcholinesterase (AChE) native function and conserve efficient amount of acetylcholine for decreasing number of nicotinic receptors.	Neostigmine	53-72	acetylcholinesterase (Cartwright blood group)	Homo sapiens	183-187
19767403-5	2010	The AChE inhibitors armin (10(7)-10(5)m) and neostigmine (10(7) to 5 x 10(6)m) caused a reduction of AP duration and prolonged the cycle length.	Neostigmine	45-56	acetylcholinesterase	Rattus norvegicus	4-8
19806080-2	2009	In this study, we used the cholinesterase inhibitor, neostigmine, to explore the mechanism of the narcoleptic IgG-mediated disruption of enteric motor function in four patients with narcolepsy with cataplexy and to identify a pharmacological mimic of the Ab.	Neostigmine	53-64	butyrylcholinesterase	Homo sapiens	27-41
19752726-6	2009	Acetylcholinesterase inhibitor reversal can cause respiratory side effects, so the lowest efficacious dose should be used: as little as 0.015-0.025 mg kg(-1) of neostigmine is required at a train-of-four count of four with minimal fade.	Neostigmine	161-172	acetylcholinesterase (Cartwright blood group)	Homo sapiens	0-20
20345342-10	2010	Among data found in the literature, many compounds have shown promising inhibition of AChE when compared to commercial standards (pyridostigmine, neostigmine).	Neostigmine	146-157	acetylcholinesterase (Cartwright blood group)	Homo sapiens	86-90
19022248-5	2009	Neostigmine potentiated the contraction of the transplanted vas deferens to a greater extent than that of the control.	Neostigmine	0-11	arginine vasopressin	Rattus norvegicus	60-63
19486927-6	2009	Ca(2+) transients were evoked by electrical stimulation of intrinsic nerves in the presence of the cholinesterase inhibitor neostigmine (10 microM).	Neostigmine	124-135	butyrylcholinesterase	Mus musculus	99-113
19515985-6	2009	neostigmine, an acetylcholinesterase inhibitor, would enhance SNS outflow, restore the neuroendocrine response, and in turn improve hemodynamic responses to hemorrhage during acute alcohol intoxication.	Neostigmine	0-11	acetylcholinesterase	Rattus norvegicus	16-36
19380255-8	2009	Leptin replacement in obese mice restored the analgesic effect of PRF neostigmine to the level displayed by B6 mice.	Neostigmine	70-81	leptin	Mus musculus	0-6
19409865-4	2009	This degradation was effectively prevented by pre-treatment with neostigmine (100 microg) in the sampling tube, but not by EDTA pre-treatment, indicating that landiolol could be metabolized by pseudocholinesterase in plasma.	Neostigmine	65-76	butyrylcholinesterase	Homo sapiens	193-213
19224517-9	2009	Controlled clinical trials have shown that the acetylcholinesterase inhibitor neostigmine is an effective treatment with initial response rates of 60-90 per cent; other drugs for use in this area are in evolution.	Neostigmine	78-89	acetylcholinesterase (Cartwright blood group)	Homo sapiens	47-67